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Abstract
Introduction
Relul tansplantation is the teatrrent of choice for ESRF. The gpaft survival is
deterrdned by several factors. One of tlre most important faclors is acute rejwtion
(AR), whic,h commonly occunl in the first 3 montbs following renral tansplantation
Ttre incidemce of AR is l540%o, but this depends on the irnnunosuppressive regime
used. The erly diagnosis md treatuent of AR is mandatory to prev€ff long-term
sequelae of AR The gold stmdard test to diagnose AR is renal biopsy which is
invasive, orpmsive, require ocperiemcd pe,rsorme! with results reportd aften 6-8
hours.
Nitic oxide (NO) is one rmique molecule with a proven role in AR However, our
interct in NO is whether it rises significmtly enrough in the peripheral blood tbal it
cm be measurd ard aid in the diaenosis of AR
We aim to find out vfuether NO can be used as ar alternative non-invasive test or
mrken to diagnose AR We also measurd NO with other post renal transplatr
complications (PRTC) GnI, tactolimus toxicity tTIl md peritoneal dialysis
poitonitis [PDPD which may mimic AR
Methods
Ethical approval obtaind. We recruited 50 corsetrtive renal transplant recipietrs
between July 2002 and 2003. The only exclusion crit€rion was any recipient with
prwious faild renal trmsplants. A fasting blood sample was collectd every other
day ard dgring otfipdient follow-up.. Serum nitrde was masured using the Greiss
reaction
Results
Out ofthe 50 recipients, 6 were o<cluded. The remaining't4 recipienfs, 19 had AR
and 13 had negative biopsic. There was a significaff rise of serum nitde (median
65.5t53 pmo|L) in AR coryard to recipien6 with a negdive biopsy goup
(41.5+23\, UTI (36.5+3E.?5) 'fT (35.5*14.88), rise in senrm cretinine >l0o/o
(44t10.5), orPDP Q7.5*23.50') (P 0.001).
Conclusion
Thene is a significart rise in s€rum nitate during AR Such a rise is not seem with
othenPRTC.
Introduction
Renal tramsplantation is the treaffie,lrt of choice for end-stage remal failure (ESRF).
Ttre intoduction of new immunosuppressive agents, better understarding of the
process of orgm tralrsplanation, and the irnprovemed in organ preervalion and
rerieval have all been tanslated into longer gpaft and patied survival (Suthamlfran
r994).
One of the main issues in tasplantation is orgm shortage. In2OMl20O7 over 3@0
pdar receivd m orga! but another 1000 died uihilst waiting for one. The
transplarf waiting list rises by 8o/o per yer. The true ned for orgal transplant*ion is
50% higho than the organs curreffly availablg md this figure is rising rapidly with
changrng derrographics in the UI! such as an ageing population md increased
incidence of type 2 diabets. This shortage of orgam can only be overcome by
inoeased orgm donation from deceased md living donors: the're has been an incroase
in living kidney donation of 2lo/o m2W7 compard to 2W6, nd of 93o/o from 2@0 to
2006. But kidney dondion from heart-beating donors fell by 14% between 2006 ard
2007 (UK tmsplan[ orgars for tansplants, A report from the Organ E]onation
Taskforce, wurw.ukffansplatr.org.uk).
Renal allogpaft failure is the fourth most @rnmon cause of end stage renal failure
after diabetes QSV1), tryperteirsion QSyA and glomerulone'phritis 06VA (Agodoa
lW1).In fbct, allograft failure fonns 2540o/o of fte waiting list for orgm mnsplanF
(Li 2001, Vadivel 2}}7r.Renal allograft failure is prcipitated by anumber of factors,
the most cornmon of uftich is acute rejection (Gjentson 2W2}
Acute rejection is still a major risk factor for renral allogfaft failure despite
advances in immunozuppresion, organ retrieval and surgical techniques. The
incidence of acgte rejection varies derpenrding on tlre immunosuppressurt protocol
use{ with reported incidence varying from 1540% (Gulmikar 1992, Morrissey
2005, Moore 2008). The frquency md sevoity of acute rejection has a direct impact
on renal allograft survival (Cecka 2000), thenefore it is imperative to diagnose ad
treat acute rejwtion at an erly stage to avoid the serious sequelae of acute rejection
suclr as graft los (Tomasoni 2008, Shrctha 2OVI). Rend core biopsy is still the gold
standard test to diagnose acute rejection (Kolodo 1998, Durkm 2006 Silva 2W7);
however, becagse it is an invasive procedwe md is fraught with complietions
including loss of the fiansplantd kidney, cliniciars may hesitate in pe'rforming it
dspite clinical supicion of acute r{ection (Rea 2000). Thene is also a group of
recipierfs who develop zubclinical rejection which is not associated with renal
dysfirnction and qihich cm only be confirmed by performing protoool biopsis. This
means that we are in ned of a non-invasive test able to diagrrose acute rsjection with
accuracy comparable to thd of raal biopsy, whicb in addition to diagnosing acute
rejection (prticulady subclinical rejection), avoids the risk and cost of protocol
biopsies, dreneby reducing the rate of graft loss and improving the outcome of renal
tansplantation (Li 2001). kr additiorL there is need of a test able to rule out other post
4
renral trmsplant complications such as urinary tact infwtiorl immunosupressive
toxicity and peritoneal dialysis peritonitis, which cm also cause remal dysfunction
Chapter 1
Nitric Oxide in General
Nitic oxide (NO) was first shown to be producd in mammals by Mitchell in 1916-
He investigafed the origin of nitrates in urine md found that the animat body excrets
more urinry ninarc than it ingests in food (Mitchell 1916). His obsenvation was
ignored until the 1970s ard 1980s whem Tmnenrbaum demonsfialed thA endogsnous
nitrate is produced in healthy adult mem md orcretd in urine (Green l98l). Theq in
1980, Fnrchgott n;1dZawaddsin showed tht vasodilatdion of a rabbif s descenrding
thoracic aorta was dependent upon blood vssel endothelium md a medialor termd
endothelial-denivd reluing factor (EDRF) (Furchgott l9S0). A few years later both
Palme,r and Ignarro, working indepenrdemly, showd that NO which was releasd
fromthe eirdothelium ofthe rr1sry and the vein had asimilar actionto EDRF @almen
1982, Ignarro 198?). They concludd thd NO has 5imila biological alrd chemical
propoties to EDRF. A year later, Palmer demonsfiated that L-arginine is the
precu$or forNO. Around the same perio4 Garthwaite id€trifid the prsgr-rce of NO
in the brain cells (Garthwaite 1988), ard Hibbs ud Marleta showed ftat NO serves
as an iffiracellulan signal within tlre activafd macrophages when in a bactericidal or
cytotoxic state (Hibbs 1988, Muletta 1988, Tayeh l9S9). Others showed thd NO is
present in the lun5, liver, kidney and bowels (Suzuki 1991, Stark 1992). Because of
ttre magnitude of its biological importance, this simple molecule was named tto
'Molecule of the Ygar" by Science Washington DC in 19!2 (Morris 1994, Stafk
l99Z). Ferid Mlra4 Robert F. Furchgott and Louis Ignarro were awarded the Nobel
prize in physiology in 1998 for the discovery of the signalling propertic of NO.
Salvador Moncad4 another notable contibutor to NO researctr, also iderfified EDRF
as an NO molecule , al{ with his co-worke'rs, showed thd NO production was
depenrdent on the pr€sence of karginine (Moncada 1991). However, it was Hibbs in
lgSZ thd reportd tbat L-arginine was the substrde for NO production Qlibbs 1988,
Monis 1994, Ztwrg I 999).
Svnthesis of NO
NO results from conversion of L-arginine to citrulline where therre is hydroxylation
of one of the L-arginine guaridine nitogen doms (Suzuki l99l,Zralrrg 1999). This
reaction is cdalysd by a group of enzymes called Nitic Oxide Synthase (NOS)'
which incorporde oxyg€n into the guanidine goup of L-argining yieldingNO and L-
citnrlline (wever 1999). Up to 50% of total body No originates from L-arginine
(Suthmthirm 1gg4). Arginine is derivd from the diet or made endogenrously by the
kidney. Citrulline is the substrate for infa-renal arginine genreration (Schmidt 1999).
In ths absemce of the subsfiate L-arginine or when it is in short supply, the same
goup of NOS has the abilrty to produce free radicals [such as zuperoxide (Oz I in
addition to NO (Davies 1995).
L-arginine is the only zubstrate that forms NO, and this rection can only be
cdalyzdby the NOS enzymes goup; therefore m increase in NO production is an
indirwt indication of upregulaion ofNOS €nzJm6.
Nitric Oxide Svnfrase (NO$ Enames
NOS enzymes belong to the cytochrome P450 enzyme goup since it has the ability
to use multiple oxiddive cofactors. There are two distinct tpes of NOS: constitutive
nitic oxide symthase (cNOS) and inducible nitric oxide qmthase (il'IOS)' d'lOS
consists of two tJDes: endothelial NOS (eNOS) md neuronal NOS (nNOS), of which
nI{OS is found in the poiphoal ad cenral neurons md also ocpressd in ortra-
neuronal sites such as tlre skeletal muscle, pancreas md kidney.
oNOS md NOS shae 50% of their amino acid sequence, but the'y vary in their
sub-cellular location, regulation, sites and €ffect on NO production (Radomskil99O,
Weisbrodt 1996).
9NOS is a dimeric complor It is activated loy an increase in intracelluls Ca+.z,
which binds to catmodulin to form a complor that is importmt for enzyme activity.
Calcium- md calmodulin-depended cNOS is uniquely associatd with the cell
membrme. cNOS is tonically active and maintains a continuous production of basal
NO by the vascular enrdothelium @edoglu 1996). It is activded by humoral,
chemical and mechanical forcs acting on the cell and intribited by cNOS
fianslocdion from the cell menrbrme and by NO. NO feeds-back on cNOS to inhibit
its activity. The activation of these enzymc is short lived amd produces NO in small
amounts (picomolc). NO mdiatq the physiologcal proccs by stimulating soluble
guanylate cyclase. This NO is known as 'tasal-NO' md facilitatq cytoprotective
functions (Vos 20M, Castillo 1996, Beckman 1996).
NOS is a te*rmeric complen It is calcium-d€psdetr and in its active form tightly
binds calmodulin iNOS is inducible in many cells; macrophagss, hepatocytes,
cardiomyocytes, neurones, microglial cells, vascular mdothelium md mooth muscle
cells @rovkovych 2001, Davies 1995, Monis 1994). iNOS is induced by endotoxitt,
IFN-% IL-L,IL-2,TNF-d ad inhibited by emdogsnrous hormons (doranethasone md
glucocorticoids), inrnunonrpprcsive dn1gs (cyclosporine and tacrolimus), md
cytokines (n-4,IL-8, IL-10, Trmsforrring gronah factor-0) (Morris 1994 Hustg
1995) Clable 1.1).
once induced, iNos is active for up to 20 houn ad produces No in nmomolan
conce,ntrdions, 1000 times greater than cNOS @avim 1995, Monis 194,1'ngrehr
1993), and NO is producd for the life of the active flzyme. The opression of iNOS
is usually associated with pdlrological states and the producd NO is cytotoxic (Vos
2@1, Castillo l9%). This NO is known as "stimulatd NO'. The l'{OS-genoated-
stimulded-No ard cNOS-genraated-basal-NO are difrerently regulded and have a
ditrerent pafroptrysiological role however they interact (Monis 1994).
The finrctions of iNOS ard gNOS are not only different, but imbalarce between the
oErssion and the activity of the iNOS and eNOS may affect cell viability in
differe,lrt ways and can contibute to patlrological conditions such as ischaemia
reperfusion injury (Pfeilsc,hifter 2OO2). The loss of iNOS may make the cell resisant
'to lrlpoxic challemge, uihereas the loss of oNOS md eNOS are lettrally daqgingto
the cells when subjected to the same hypoxic challengs (Pfeilschiften 2W2,
Golig*rsky ?002). Ther*fbre, seleetivc inhibitioea *f iNOS and spering *NOS is e3'to-
protoerive against isehaemia {Ling 199S). Although all NOS praduees the same }'{CI
mcleeule, th*ir activity erld fimetion vastly difTer dere tc differenees in ths tempnrar"v
profil* of N0 *utpuf and the topopaphy of N0 release by eaeh Nos. Moreover,. the
higtrr *utput of NO produetion by iNO$ mey suppr€ssiinldbit the activity cf eI'{O$
{fioligorsky zeAU.
Membrane &orand
ed*iun* E*Pendent
ealrn*dulin Sop*ndent
Cofactor dependence IndePendent
Constitutive NOS
trridoth*lial cells, platelet*,
*raeular densa, neuf,*nes
Yes
Short lived" piccmoles
Ach, BK histamine,
APPIATP, thronrbin,
exeitatory arnino arids"
shear stress
Dimethylarginine
Inducible NOS
I-euecrytes, maerophages,
Kupff*r eells, hepatooytes,
mesangial cells
No
Dependmt
Independent
&ependent
$ustained, nanornoles
Kndotoxin, Cytokines
Giucocortieoids
&elease
"{efiv**ors
Xnhibit*rs
Tahle 1..1: Se*tures the elifferenee ir*tween cl'l*$ and iN&$. Ach; aeetylenroline, EK; trradykinin.
{ruodified from Snzuki }991}"
*K$-sxpws$ps&Siff"gtplt& S$essw
Resting eeltrs do nat express iNO$ but they have the eapaeity to dCI so when
stifil*lated. This eapaeity is fcund hoth in ilernrwe eells sueh as maerophages and
'l f)
non-immune cells such as he,pafocytes, vascular smooth muscle cells, kidne'y cells md
fibroblasts (Davis 1995, Morris 1994, Morrissey 1994, Ndhm 1991).
once iNos is stimulard, there is a delay of several hous in No syntheis md
production This is because ofthe timetaken to formthe essential cofactors needed to
induce orpression of iNOS and its syntlesis. At the level of the mRNA this was see'n
3 hours post-stimulatiorU the circulding nitrate (NO-t levels peak at 12 hours ard
retun to baseline levels after 24 hours (Monis 1994).In roden8, the susaind high
levels of iI.{OS exprosion may last for a few days (Morris 1994)' The stimulating
factors thaf induce the exprssion of iNOS are different from cell to cell. iNOS
pdhways wene first discovened in murine macrophages. They exprss high levels of
NOS upon exposure to lipopolysaccharide (LPS), but a strong s)'nergy occurs when
interferon-y is added (Morris lgg[).In rodenrts, marophago rspond vigorously
when stimulated by LPS and IFN-y. When the culturd rat he'patocytes are stimulated
by the conrbindion of LPS, IL-l, TNF and IFN-y, there is m increse of iNOS
mRNA levels md NO qmthesis. Humm cells demonsfiate iNOS pafhways brf they
require prolonged CIposure to stimulating facton. Ilumm cells show variability in
their response to iNOS elpression when compaed with rodot-cells, which may
indicate that hurnan iNOS gene regulation is different from that of rodents Mles
1995). Humm pulmonary artery smooth muscle cells and humat cardiac myocytes,
when exposed to II-1, TNF and LPS, show only a minor increase inNO productiorl
whereas humm hepatocytes €xhibit a good iNOS activity similar to that seen in
rode,lrt macrophagc. This rmponse in hepafocytc enabled cloning of the human
iNOS gene, which shres only 80% of the rodent iNOS, while human cNOS shares
gtr@ter than 90o/o. This may explain the diffe,rent rsponse seen betwe€n the two
€nzymes (Monis 1994 Miles 1995). Thereforg the rcponse of cells to stimulation
ll
may var.y from one to another, withinthe same cell tlpe and from specis to species,
and there is asignificant spwies difference in iNOS orpression
Tvnes ofNO
The tlpe of NOS that producs NO wiil govern its effect Up-regulafion of el'{OS
general€s NO in small amounts; this is the cytoprotative basal-No producd dwing
ptrysiological firnctions. Up-regulaion of iNOS generates NO in large amounb; this is
cytotoxic stimulddNO produced in pahological states @avies 1995, Kroncke
lggT). Cytotoxicity and cytoprotectivity are determined by the local conce,ntdion of
NO, i6 final degradation products at a particular site and the redox state of the
microenvironment.
Basal-NO is found in the endothelium and most cells of the body. It was found'to
be preseril in the brain cells, lunp, tiver, kidney and bowels where it contributc
direcfly or indirectly to organ firnction within physiological stats (Suzuki 1991, Stark
1992, GstSwaite 1988). The m{ority of NO is generdd from endothelial cells,
transporting epithelial cells and the nervous system. It is produced unden
physiologicat conditions as a mgans of modulAing blood pressure' renal
haemodpamics and sodium orcretion; hence it is also known as'Uas'mod)'namicauy
RenayActiveNO" @ayhs 1998). This endogurously-genrerdedNO, in additionto the
NO generad from diet md inhaldio4 is knounr as "total systemic nitic oxide"
(Baylis 1998, Schmidt 2000).
The main source of stimulafed-No is phagocytic leukocytes such
polymorphonuclear leukocytc @MN), monocytes and rnacrophages. During
all
the
l2
course of acute or chronic inflammatory processes or in acute immune rwponse
situdions such as acute allogfaft rejectioq activafied macrophagc are the main source
of iNOS up-rquldion and NO production (Sua*i 1991, Lmgrehr 1993, Vos 200/.,
Castillo 1996, lVheeler L997,Mles 1995).
Mechanism of Production of NO
The basal-NO production is ongoing in the circulafion depending on humoral,
cellular and pbysical factors. NO interacts with the endothelial and blood cell
elem€nts and is responsiblo for blood vesel relaxation The binding of NO to
Guanylafe Cyclase causes the production of cGMP, leading to protein
phosphoryl*ion and smooth muscle relaxation firer€forg loss of endothelium ard
absenrce of NO would prevent the vessel from regulating its ov'ln tone. Physical force
such as that cawd by the circglation allows tho cells to up-regulate or doum-regulate
NOS activity, rsulting in NO production or inhibition respectively. Within the
circulation, physical forces are convented irfo chemical signals inthe fonn ofNO that
mediate the vessel wall reaction
ptdelef,s and leucoryto uo the celt typc which are rspotlsible for the ongoing
release of NO in the circulation Ttre intenactions betwst NO and platelets make NO
atbrombo-rquldor in thrombus formAion It acts by prwenting pldelet adhesion to
the endothelial cell surfacs by activaing soluble guanylae cyclase. NO is atso
involved in leucocyte interactions wittr the vqsel wall. It inhibi8 neutrophil
aggregation and adhesion to the blood vessel wall and prevents migration md
chemotaxis of mononuclear cells (Davies 1995, Kub€s l99l).
l3
The stimulated-No production is triggerd by immune response, infection and
sgrgical sfess. Immune r6pomes suc,h as acute renral rejection are a potent factor in
stimulding up-regulation of Nos, leading to m increase in No production urhich is
linked to the production of various types of cytokinc @rovkovych z00l,Hesmskerk
200Q Algenr 1999, Hirabayashi 2005). Lipopolysaccharids (LPs) md endotoxins,
both released in acute infectious conditions, ae pote,lrt inducers of iNOS. LPS is a cell
wall component of manry bactoia such as E.coli, md cm induce host ddencc for
kiiling of bacteriq cytokine production and up-rquldion of iNOS. Although during
endoto:raernia most NO is generated by up-regUldion of iNOS, some recelrt reports
suggest thd in the initiat stages of endotoxaemi4 up-reguldion of oNOS may also
contibue to NO production @rovkovych 2001). The ongoing release of LPS and the
impaired renal cleararce of NO od-produc'ts which is usualty seen in septic patients
are the two other reasons for raised levels of NO Qlee,mskok 2006). In sepsis there is
a 40-fold inqease in the up-reguldion of NOS within the kidney; this is associated
with only a two-fold increase in senrm NO but a significam increase of urinary NO,
indicating that NO is produced mainly in the kidney. This rise in iNOS and NO
radicals within the renal tissues could be responsible for renal injury dwing sepsis
(tleemskerk 2006, Schier 20M, Wan 2W3). Septic shock per se leads to over-
production ofNO (tlirabayashi 2005, Endo 1996).
Stimulated-NO production could be relaed to the site of infestion and type of
p4trogen During gastoenrtuitis or respiratory tract infwtion there is m increase in
local NO production that is fianslatd into a rise in senrm md urinary nitrato. NO
production is highe,r in particular bacteria and viruses compand to others (Ahren
r99g).
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Surgery also induce the release of various tlpes of cytokines including TNF-0, IL-
I,IL-6,II-S Slirabayastri 2005). The site of NO production is thought to be fte
..disordend organo'o such as the liver, rather than the surgical wound i$elf This is
because it is the organ cetls thd have the abillty to up-regulde NOS, while
neutrophils, the cells pr6ent in the woun4 csrnot produce NO in significantly large
arnounts (Hirabayashi 2cfl5, Denis lgg4). Ttre poipheral white cells have also been
cited as the source of No, particularly in sepsis (Miles 1995, Atnin 1996, Tzukahara
l99S). Whdwer the final source of NO productio4 it evortually diffirses into the
main bloodstream ufrere it is detwtable. NO production is thougfut to begn during the
operdive perio4 but it tako 2 Wpostopodively to peak (flirabayashi 2@5), since
this is the time needed for cytokines to be formed md producd-
Mechanisn ofAction of NO
NO has unique charactsistic: it is a colourless gas, soluble in wale'r, lipophilic ard
readily permeatc biologicat membranes. It cannot be stored and does not require
orocytosis to leave the cells. Furthermore, it does not act on specific ortracellular
receptors but instead diffirses freely and binds to infiacellular recoptors (Suzuki 1991'
Davies 1995). Therefore, the ability of NO to diffirse across cell membrmes and to
bind to haem ad non-haem iron proteins explains the mohanism by which NO
reaches intracellulr targsts. This maks it a usefirl infiacellular messenger since it
difrsgs througfr cells with little consumption or reaction with othen intacellulan
elements @eckman 1996, Davies 1995). NO has the ability to bind to a wide vadety
of proteins and enzymes, facilitating a lrge number of functions, some of which are
l5
cytoprotective and others cytotoxic. It also binds with different enzym6 during
ptrysiologicat or pathological conditions. Binding and activation of soluble gumylde
cyclase produces guanosine 3,5 cyclic monophosphale (GGMP), s/hictt has myriad
cellular effecb such as smoottr muscle relordion and inhibition of pldelet
aggregation. Activation of soluble gumylafe cyclase is the most relevafr
physiological action ofNO (Davies 1995).
NO interacts with thiol goups zuctr as cysteine, N-acetylcysteine and glutanhiong
fonning S-nifiosottriols, which cm influence the cellular furctions sf thislgsntaining
enzymes (Shah 2003). S-nitosothiols are biologically active md perform the sarne
functions as NO (Stamler l9Y2).
The othe,r mechanrism of action of NO is its int€raction with superoxide urd
formation of peroxynitite md pooxynitite-induced nifiatioq leading to cellular md
enrvmatic rqiury (Shah 2m3). This reaction is prwented by superoxide dismuhse.
Deeradation of NO
NO has a short half-life of 30 seconds, which ariss from its reaction with
superoxide in vito, and its reaction with haemoglobin and othen reactions in vivo
@eckmm 1996). NO is an unstable molecule and rapidly oxidizes to stable end-
producs, namely nitrite and nitrde both in vitro srd in vivo. Nitite i$elf is unstable
in the presemce of FeF hasm or fiansition metals when it is converted to nitate.
NO is also converted to other irterrredide mstabolites such as nifrosoglutathione,
nitrosoalbumin and nitrosohaemoglobin The presence of intermdiate metabolites in
large qumtitid may orent biological effwts (Wemrmatm 19913); it is not knownwhd
l6
proportion of NO goes through which inte,rmediary pathway, but most of these
intermediaries eve,lrtually also yield nitrate. The reaction of NO with superoxide
forms peroxynitrate, which also forms nifiate (Suthanthiran 1994). The final
production of nitrate, an inactive molecule, is the most effective way of inactivating
NO (Tsikas 2005). [n tissues, once NO forms it diffises rapidly out into the vascular
compartrnent, where it is destroyed by haemoglobin (Bechnan 1996). Within the
circulatiorl NO is consumed by red cells or vascular smooth muscle cells (VSMC)' It
combines rapidly with oxyhaemoglobin (Hbo2) to form methaemoglobin (MetFIb)
and nitrate, or with haemoglobin to form nitosohaemoglobin (UbNO), which is
converted to MetFIB and nitrate. NO can be converted to nitrite bsfore it diffirses into
the red cells. However, nitrite follows the same pathway as NO within the red cells
and forms HbNO, MetHB and nitrate. Nitrate is an inactive molecule that passes into
the plasma and is cleared by the kidney (Figure l.l) (Wemrmalm 1993, Tsikas 2005).
VSMC EC
1 Figrse 1.1: Metabolism of NO in vivo. Copied from Wennmatn 1993. EC @xtra Cellular)
NO is a free radical and interacts with otlrcr free radicals. Free radicals may also
influence the functiors of NO. Free radicals are aty species capable of independent
t7
enistence and are che,rnically highly reactive (Weight 1996). Some of the free radical
moleculs are molecular oxygen (Oz), superoxide (Oa-), hydroxyl (OH'), peroxynitrite
(ONOOI and trmsition metal-ceffied radicals such as perferryl radicals (Weieb
1996). They are also knoum as reactive oxygen species (ROS). NO acB as a free
radical scaveng€r and thus a cytoprotective factor (Cooke 1993, Weight 1996); on the
other hand, NO can combine with superoxide and forms poox5mifrite' a potent
oxidmt which decomposes to form a hydrox$ radical thd can carxrc cellular injury
(Trujillo 200E). Since free radicals ae highly reactive molecules, their site of action
must be close to their site of formdion Their targets are cell membrmes, structural
proteins, enzyrr6ric proteins and DNA The lipids found in cell membranes are
pooxidisd and the proteins prese,ff in the structurd md enzymatic proteins are
dendurd (Wei$t 1995, RatYch 1986).
Interactions between NOS. NO and ROS
The tlpe of NOS enzymeupregulafed dictates the anrount of NO released in the
microenvironment The final out@me of the effec* of NO is determind by the
concentdion of NO, the site of release ofNO alrd the duration of action ofNO.
Tramsient spike-like NO gsnerafion carsed by eNOS activation is critical for
activation of haerr-containing enzymes including soluble gumylde cyclasg as well
as vasorelaxation, di-apoptotic progr@me and protection against oxiddive sfress.
Sustained high epfput of generAion of NO caused by iNOS activdion rnay turn on
variors functions zuch as apoptotic action, lipid peroxiddion or DNA damags Gigre
r.2).
l8
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figure 1.2: Vadous functlons induced by eNOsgenerzf.ed-NO and iNOS'generated NO (copied
from Goligorsky 2002).
The stimuldion of il.{OS during inflammatory processes is associded wit}t high
production of NO and ROS. The inte,raction betwe@ NO and ROS produce potent
nitrosating ageds. Pe,roxynitite (ONOOJ results from the rsction of NO with
superoxide (OzJ and dinifiogem tioxide (NrO3) results from the reaction ofNO with
molecular oxygen (Oz). These agents tigger signalling by altering protein kinas6,
protein phosphatises and trmscription factors [nuclear factor-rB (NF-rB) md
activator protein-l (AP-l)l (Marshall 2AW, Pfeilschifter 2000).
NO is thought to regulate an increasing number of genes. Once the cells are
orposed to NO, there is activation or silencing of gemes via transcription factors
leading to up-regularion or down-regulaion of groups of enz5mes which include
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protective antioxidanrt defenrce enzymes such as superoxide dismutase,
haemoxygenase and pro-inflammatory mediators (chemokines IL-8) (Pfeilschifter
2002 Grisham 199).
ROS are similar to NO; in small arnour$ they act as infia-cellular messengers, btf
in large amoun6 they are part of the defensive meclunisnr ROS cqr be produced by a
goup of orz5rmes, such as NADPH-oxidase, xanthineoxidase, cyclooxygenase and
notably NOS (Pfeilschifter 2Wz Suh 1999). If ROS ue producd in amoun8 large'r
than the cells can handlg, a state of "oxidative sfiess" resulg. During oxidative sffess,
there is also upregulation of protective genes and down-rquldion of other genes
(Pfeilschifter 2002, Pfeilschiftsr 2000).
The relative amoufts of NO and ROS produced could determine the cellular
outcome (ryoptosis or necrosis). The simultaneous gene,ration of radical molecules,
and their interaction and opposing effect on ce'rtain gen6, may result in quite
dramatic c,hanges in enzyme expression This orplains the various paradoxical
biological effects of NO. Within physiological stateq there is a low ou@ut of NO and
low production of ROS, along with activation of soluble guanylate cyclase and
generation of gGMP @feilschifto 2W2).In palhological conditions, the complexity
of the multiple roles of NO and ROS could be multifactorial. The RoS-genraaring
enzymes are constitutively exprssed in tissues and produce ROS with minimal delay,
while iNOS expression requiro a period of several hours to el4se before NO
production oocurs (KurE lgg4, C*tdl2002). Moreover, the half-life and the range of
diffision ofNO md ROS are also different (Radeke 1990, Kunz L994).
NO md ROS have sn impact on the expression of the €nzyms thal generde or
metaboliso them (fedback). This may alter their availability an4 as a consequence,
change the ratio of NOIROS, urhich will cause a shift in gears with regards to
2A
inflarnnatory gene ocpression. NO controls its biosynthetic machinery as it targets the
fanscriptionat regulation of iNOS. NO functions in a positive feedback loop that
speeds up and sfiengthens its own bioqmthesis, and this forms the basis for the
excssivo formdion of NO in acute and chronic inflarmration disease (Pfeilschifter
2W2). ROS also potentiatc the expression of iNOS and firther amplifies the
ge,lreration of NO. In confiast, NO inhibits ROS generation, teading to alteration of
the NO/ROS ratio and thereby oeating a dominding 't{O statd'. NO-triggered
amplification of iNOS orpression could bo limitd simply by short supply of the
subst6e L-arginine. Reduction of L-arginine concenfidion can become rate-limiting
for iNOS expression (Cuzzocra 1998, Pfeilschifter 2002, Goligorsky 2002, Shah
20p3).
SrrmmAny
Although NO is the smallest product of mammalian cells in terms of the amount
producod, it mediates a diverse rarge of fimctions. The type of NOS, the amount of
NO produced md the site of ie synthesis detennine the final fimction of NO within its
environmen! and this is crucial in determining the physiological and
pattrophysiological etrects. NO contibutes to fte physiologrcal fimction of most
organs, including the kidneys, liver, gasfiointestinal tract and brai4 and it is also
implicafed in their dpfirnction, uihich can lead to glomaulnephritis, hlperte,lrsion and
cirrhosis. Under physiological conditions, oNOS produces NO in small amoun8 and
only trace amounts of ROS are available to scavenge NO, indicding that NO
chemisfy will dictate functional cell responso. Therefore, NO is benreficial ad cyto-
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protective when it is a free radical and a scaveng€r. Unden patlrological conditions,
when a tiving cell is subjected to sfiess or change, it ad4ts to charges by expression
of m inducible system of enzymes (iNOS) md mediators which provide an
appropriate response. Lrflammatory cytokines, e,ndotoxins md LPS prime md activate
iNOS, which generates the large amouds of NO thaf in tum cause nitrosation anrd
oxiddion of cellular proteins, and formation of toxic producs (peroxynitite). The
deleterious effecb of NO can also arise as a result of consuming lage amounE of
oxygen, since NOS requires two oxygon molwules for every NO molecule producd
@avis 1995, Pfeilschifter 2@2).
Conditions:
Kidnevs: Phvsiolow
NO's role within the kidney is complex and diverse. The diversity of NO function
can be explained by the vaious orprmsions and regulations of NOS within the renal
tissues. NO effects are seen in relation to glome,tular filtration rale (GFR),
tubuloglomenrlar feedback and the ju:rAglomerular appardus (Figure 1.3) (Mundel
1992, Wilcox l992,lto 1993).
NO is an important mediator of a number of physiological processes within the
kidney, including the homeostatic regulation of glomerular, vascular ad trbular
functions ofthe organ"
CNOS is present in the glomenuli macula densq the collecting duct and the inner
medullry limb. Ths NO gernerded here regulafes the glomeruli mioocirculation by
modi$ing the tone of the afferers artenioles and mesangial cells. In the macula densa'
NO causs vasoreloration of the afferent arterioles, theneby modulating the
tubulogtome,lllar fedback response by decresing affered artedolar vascular tone
and incresing glomerular capitlary pressure (Wilcox 1992, Mundel 1992)'
Reabsorbed solutes by the tubulan cells of macula densa influence the rynthsis ofNO
within the mactla densa (wilcox 192,lto 1993, McKee 1994). This proces also
initiate the tgbuloglomerular feedback response. NO's vasorelaxdion effect is furthen
entpncd by the fastttntit is the natural antagonist of vasoconstrictive ag€nts such as
angiotensin II and enrdothelin I, which are continuously interacting md modulating
renal haemodyranrics. Thenefore, NO is considered to be a ve,ry potent rquldor of
inta-remal haemodyramics @lum 1 998).
INOS is orpressed tonically in the vascular smooth muscl6, gfanular cells and
proximal tubule (Roczriak 19%). At each site NO canies out a diffenenrt role: in the
vascular smooth muscle, found mainly in the afferent and efferetr arterioles, NO
plays an important role in the reguldion of glomenular capilary blood pressure,
glomerular blood flow and glomerular cqillary ultafiltration coefficierd (Morrissey
1994').In granular cells, NO modulate the release of reni4 which plays a role in the
tubuloglomerulr feedback ard thereby confiols glomenrlar haemodynamics. Finally,
in the proximal tubule NO is thouglt to be a regulator of Na trasport
Thus, it is obvious ttrat NO modulafs the vasculu tone @eierwalters 1992) afi
renin relese (Schricker 1993), and influencs sodium md water haemostasis within
the hdney.
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Morrissey localised iNOS to the outer medulla of anormal rat kidney. When the rat
kidney was subjected to stimulation by LPS or cytokines, up-regulation of iNOS
could be identified in the resident leukocytes found in the cortex, while macrophages
like type II interstitial cells w€re found in the outer medulla, and endothelial cells
were seen within the outer medulla and in tubular cells (Morrissey 1994).
NO production is not limited to the endothelium; it can also be generated by
mesangial and inflammatory cells infiltating the kidneys. Besides its vasodilatory
functioq it inhibits the proliferation of mesangial ard smooth muscle cells. It cal also
act as a growth factor in modulating the growth of vessels and glomeruli. It is clear,
theru that NO is a fwrdamental component of the cellular milieu in the kidney (Blum
1998).
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NO and Renal Disease
The complex interaction betwwn different NOS isoforms and the conplexity of
NO actions are conributing facton in inducing renal iqiury in ESRF, acute renal
failurg glomerulonephritis and ischaemia reperfirsion injury (Cattell 2W2).
NO has beor implicafed in the pathogenesis of different renal pathologies, ufiich
include:
l. End stage renal failgre (ESRJ) and renal replaceme,lrt therapy
(haemodialysis and poitonal dialysis)
2. Acut€ renal failure (ARF)
3. Glome'ruloneplritis
4. R€nal iscbaemic reperfirsion tqiury
5. Obstrtrctive UroPAhY
End Stase Renal Failure (ESRtr)
In ESRF, every step of NO gemeralion is intribitd or deficient, creding a "state of
NO deficiency- (Blgm 1998, Vallance 1992). The deficiency of NO production in
ESRF could be cagsd by a number of mechmisms, including an increse in
enrdogenous NOS inhibitors zucih as Dimethylarginine (DMA), a loss of firnctional
renral mass, m arginine deficiency or increased levels of oxidat sfrss (Davies 1995,
Schmidt 1999, Wever 1999, Schmidt 2000, Cdlell 2N2). Both the "total systemic
NO production" and the 'traemodynamically renaVactive NO productionl' are low in
pdient with ESRF, and this resul8 in low urinary NOx (Sdrmidt 2000, Cattell zwz
Vallance 1992, Schmidt 1999). Plasma NOx was not significantly higher in the ESRF
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Soup coqard with the normal goup because of reduced NO production md
reduced renal clerance. ESRF patients on haemodiaylsis or peritoneal dialysis are
found to have high levels of serum NOx despite low "total systemic NO production",
and this is thougtf to be due to complete loss of renal clerance dtd high production
of NO from other sites such as the cenebellum (Sclmridt 1999). Thereforg plasma
NOx alone may not be atrue reflection ofNO production. The rise in the levels of the
NOS inhibiton asymmefiical dimethylarginine (ADMA) md symmenical
dimethylarginine (SDMA) cause the inhibition and rduction of "haemodynmrically
renauactive No production" (Schmidt 20m). vallance reportd the presenrce of
circulating mettrylaredarginine analoguc (ADMA and sDMA) in ESRF pdients;
these can inhibit NOS md NO syrthesis. Endogenous ADMA riss in proportion to
the increase in senrm cretinine, ard is detwtable in humm urine and plasrra (Blum
1993). N- monometlryl-L-arginine (I-NMMA) mother odogenous
mettryldedarginine analogue, may also accumulate in ESRF pafients.
The loss of renal rnass has two impacts onNO production: firstly there is doreased
inta-renal NOS activity, as demonsfated inrats with reducd renal mass @lum 1998,
Aiello lggT), and secondly there is low endogenous Larginine generation due to the
lack of functional r€nal mass, which is the main source of enrdogenous L-arginine
supply aften diet En4mes such as arginase and arginine dcarboxylase may also
compete with NOS for L-arginine, frrrther reducing its availability in ESRF (Blun
1998, Vallance 1992). Citrulline is the main subsfiate for generdion of inta-remal
arginine, ard this accumulds in the plasma supportiag low e,lrdogenous arginine
genreration (Schmidt 1999, Schmidt 1999).
tlaemodialysis (HD) may induce m inflammatory response and cm stimulate NOS
up-regulation and increase NO generaion. Despite this, there is a low production of
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NO becalse HD increases the loss of arginine (Wever 1999). PlasmaNO levels fall to
confiol levels post-HD, suggesting that HD adquAely replacc the kidney in clering
NO. Howeve,r, HD does not clear the accumulated endogenrous NOS inhibitors
(ADMA) when measured pre- and post-IID (Schmidt 1999). Peritoneal dialysis @D)
does not stimulde the production of NO as HD dos, nor does it not clear NO as well
when compard with HD (Schmidt 1999). NO production is low in pdierrs on PD,
but they bave higho levels due to an accumuldion of NO arising from poor renal
clearance. The poitoneum per se dos not stimulat€ iNOS except in the presenco of
peritonitis where iNOS is stimulated (S&midt 1999).
Acute Renal Failure
Acute renal failure is characterisd by an abnrpt md reversible kidney dysfunction
The causes are broad" ad include isctraemi4 a neplrotoxic agent md sepsis
qmdrome. The insult to the kidney can result in vascular, glomenular md trbula
dysfigction (Goligorsky 2002). NO has variable effwts depending on the stimulated
NOS, the site of its production, the duration of iA effect and the associd-d prdmse
-:r
ofROS.
There is ar imbalance betwe€ilr the orpresion and the activity of iNOS and cNOS
in ARF. Inhibition of oNOS is one of the hallmarls of endothelial cell dysfunction
seen during acute renal injury. The endothelial cell dysfimction is followed by
induction of iNOS, increased production of NO md ROS md ge,lrerdion of
peroxynitrite. This will lead to the dstnrction of tubular epithelial cells. The high
output of NO will inhibit cNOS, causing furtlrer insult to the kidneys (Goligonky
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2N2). NO atso inhibits complen I respirdory chain e'names, adding to its
cytotoxicig (Clementil998). The renal tubular cells are resistant to hlpoxic insult
when depleted of iNOS, but the same cells sustain lethal damagp when depleted of
gNOS. This re,lro-protective effwt causd by selective inhibition of NOS against
ischaennia is possibly due to inhibition of NO production than, although shaned by
cNOS, may have a diffenerf outcome as aroult of its action (Ling 1998).
Glomeruloneohritis
In glomenulonephritis there is stimulation of iNOS and increased production of NO
and other ROS (Joles 2WZ). kr the early stagBs of glomerulonephritis, NO peala; this
is associated with macrophagB ffilfiation (Jmsen 1994). At later stages of the
disease, there is a decline in NO levels despite the persiste,lrce of macrophage
infiltration This phenomenon is due to the biphasic expression of iNOS where high
levels of NO will down-regulate iNOS by inactivation of nucler factor-xB (NF- xB)
(Cattell 2N2). Selective inhibition of iNOS is reno-protective, however non-selective
inhibition of NOS can have delsterious effects on the kidney. The,refore, when the
fimctions of all NOS are blocked the deleterious eff@ts of intribiting eNOS will
prevail oven the benefits of inhibiting iNOS. This is an indication thd NO may have
some protective roles within the kidney, such alt opposing the increased
vasoconsfiction in injured glomenrti (Gohgonlcylggg). This is well demonstrded in
admal models: glomenulonephritis in humms shows up-reguldion of iNOS md
suppression of eNOS. iNIOS is expressd within prenchymal tissus but not in
infiIfiating macrophages. The initiat reponse to injury is r4id induction of NOS md
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increasd generation of NO, which is cytotoxic and cytostatic (Cattell 2W2).
Supprcsion of eNOS and loss of eNoS-genrerated NO will furttrer aggravde tissue
damagp and promote inflammdory reactions in acute glomerulone'phritis Sleoinga
2W2).
Iscft aemia Reoerfirsion Iniun fl RII
IRI rnay be precipitrted by sepsis, shock and organ transplantation IRJ in the
kidneys cagses impairment of gtomenular and tubulr function Impairment of
glomerular funstion rsults in a rise in serum creatinine and ure4 wbile tubular
dysfimction causs a rise in fractional errcetion of sodium (FEw") alrd ssum lwels of
aspirtate fimsaminase (AST) (Char 1999). In the post-ischaemic phase the
endothelium becomes refractory to the vasodilatory action of NO. At the same time,
there is an increase inthe swretion of endothelin Ttris leads to alteration of the 
o'nitric
oxide: endothelin ratio". Both actions cause rduction in remal blood flow (RBF) md
GFR (Weigbt 1996). Renal injury can be further accelerdd by other factors,
including PMN athaction and activatior\ genroation md formation of ROS, formation
of pro-inflannndory cytokinc (IL'1P,IL-6, II-8, TNF-u,), orpression of enrdothelial
and neufiophil adhesion molecules [vascular cell adheions molecules (VCAM-I) ad
intercellular cell adhesion molecule-l (ICAI\,I-I)1, overproduction of vasoactive
mediators and fonnation of RNS. All facton contribute significatrly to ischaemic
acute tubular necrosis (ATN), leding to acute renal failure.
The exact contribdion of NO to changes in renal firnction druing udurY is poorly
understood, frough it is thoqltr thd NO effects are produced at the cellular md
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microvascular levels. All 3 isoforms ofNOS are widely orpresed inta-renally. They
produce NO, wtrich is a potent vasodilator, and are natural vasconsfiictor artagonists.
Inhibition of all 3 NOS isofonns has a deleterious effecq which will cause er(cssive
vasoconsfiictioq oracerbate orgm ischaemia and lead to microvascular tlrombosis.
However, selective inhibition of iNOS could be reno-protective. Weight postulAed
thd NO has a biphasic role in orpe,rimenul renal warm IRI. Iluring ealy stages of the
ischaemic phase, there is upregulation of iNOS, and production of high levels of
cytotoxic [.{OS-genoated-NO which generates large amounts of peroxpitrite md
hydroryl radicals. This oxidafive stres causs injury by direct oxidm and protein
tyrosine nitrdioq DNA damage depletion of NAD and ATP ard ultimately cell death
(Weight 1996, Chdterj ee 2N2). At a laten stage, NO becomes cytoprotwtive. NO
inhibits the sequotration of activded neutophils ard maintains RBF, which is
facilitated by up-regulafion of cNOS and the generdion of cytoprotective eNOS-
generated-NO. Intribition of iNOS exprcsion and the release of large quartitie of
il.{OS-generded-NO, which firther reduces the levels of perox5mitite, will reduce
renal irdury by IRI (Clratterjee z$Oz,Wetgtrt 1998, Weiglil 1999).
The up-regulation of eNOS and iNOS takes place d two different pe'riods with
different effects. At two hours of ischaemia there is up-regulation of el'l0s and a
production of NO in srnall amomts thd lowers the perfirsion pressure of the orgarl
However, six hours after perfirsion there is up-rqgulation of iNOS, which results in
the production of large amounts of NO urd the genreration of free radicals. The
production of free radicals nay compromise the vasodilatory effwt ofNO. Subjwting
the kidney to short poiods of ischae,mia (before ischaemia reperfision occurs) may
make the organ more tolerurt of ischaemia; this is called ooischaemic proonditioningi'.
This tolerance to ischaemia repe,rfirsion injury damage could be amibwed to m
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increasd release of NO (Torras 2OO2). Ischaemic preconditioning is a corylex
proc€ss which involves activation of the protein kinase C (PKC) directly or indirectly
@oumey 2D7).Indirect activdion of PKC involvs up-regulaion ofNOS. Evidenrce
slrows that both eNOS-genoated-NO and iNOS'generated-No play an important role
in the protective €ffect of ischae,rric preconditioning (Torras 2002,Ymasowa 2@4).
Jefayri demonstated th*, u increase in NO production was due to al increased
orpression of eNOS (Jefayri 2000). The ability of the kidneys to produce NO eve'n
when exposed to long poiods of ischaemia, and the ability of the NO to be a
vasodilalor and inhibit leukocyte adhenenrce and plafelet interaction with endothelium,
indicaie the cfloprotective role of NO in IRI (Kin 1995, Pryor 1995, Chan 1999'
Chderjee 2002).
Obstnrctive Urooathy
Obstnrctive uropafhy leads to renal injury and fibrosis. In obstnrctive uropanhy
there is an increase in NO activity and generdion NO md NOS play an arti-fibrotic
protective role aften the onset of ureteral obstruction eNOS is the predominalrt source
of NO within the obstnrcted kidney and the eNOS-generded NO confers the mti-
fibrotic and protective role (Chevalio 1992, Morrissey 1996, Wheeler 1997, Chng
2W2). The absence of iNOS leads to a compensatory increase in the production of
eNOS-genaated NO Slumg 2000). Chumg ttrought thar both NOS ad eNOS are
protective moleculs which protect against tissue damage, as he showed using
obsfrustd ursters in ras (Chuag 2005).
Urinary ogflow obstnrction (UOO) can be transplant- or non transplmt-relaled.
Transplarf-relded UOO is of of two 6/pes: ureteric ischaemic stenosis and ureteric
anastomotic stenosis. Non trmsplant-reldd U@ is mainly caused by benign
prostate ttlperfophy.
In UOO there is a increase in serum md urinry nitrite for a period of timg as
well as up+eguldion of eNOS md iNOS during ureteric obshrction. The initial rise
in serum and urinary nitrite is due to arise in eNOS; a zubsequenrt rise, which may last
for 2l days post ureteric obstuctiorU is scondary to up-regulation of iNOS, wtrich
then declines (Huang 2000, Chang 2002, frrou 2@3, Chuag 2005). Since bladder
epithelium contains NOS, they rnay confibute to the levels of urinary nitrde
Sleemskerk 2006). Chevalier et al demonstrated that during unilaferal ureteric
obsfirction there is an increse in NO production in the obstucted kidney, and this is
partly to coufferact the release of vasoconstrictive ageffi such as alrgiotensi4
thromboxans and endothelin (Chevalia lW2).
NO in the Lunss
Both cNOS ard iNOS are €xpressed in the hrng tissuc and NO is detectable in
exhald air, localising its production to the airways (Asano 1994, Asmo 1995). NOS
md NO corxribute to the bronchial and vascula tone and to the defenc€ mechroisrns
(Schmidt 1994). The coerdstence of cNOS and iNOS in human alveolar and bronchial
epithelial cells confers a defensive banier at the airlsurface interface and prevents
airway hypenreactivity (Asano 1994). The airway epithelium has the capacity to
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tonically expr6s iNOS unde,r basal conditions, but not the poipheral human lung
tissues orthe residerf macrophages (Guo 1995).
NO is thought to have a bronchodilatory effect by acting on the nonadrenergic
noncholinergic (NA}.{C) pathway. Irffavenrous or inhaled nitates are effective
relaxants of airway smooth muscle cells (Guo 1995). NO also acs as a vasodilator in
the lungs, however the pulmonry circultion is less influenced by NO when
compard to the systemic circulalion (Schmidt 1994). NO is implicdd in the
pahogenresis of lung inflammdory diseses. Asthmdic pAients have high levels of
NO intheir oftaled air. Inhald corticosteroids down-regulae NOS and decreaseNO
productio4 there,fore losing the bronchodilatory effects of NO as well as its qrtotoxic
effects against mycobacterial and fi.rngal infection This supporB the protective role of
iNOS and NO in the airways, which medide cytotoxicity against bacteria, viruss,
fungi and protozoa(Grc 1995).
NO in the Brain
In the brairU neuronal gNOS is localised to 2%o of cerebral cortical neuronsl and is
also found in the vasculature of tho dendrites and o(ons. NO acts as a
neurotalrsrnitter but it differs from othen neurotansmitters within the brain (Figure
1.4). It lasts longer ttun acetylcholine. The diffirsibility of NO means it is able to
diffirse to several million synapses and take paxt in various functiora (Beckman
1996).
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Frgure 1.4: NO in brain al a neurotranrmitter.
NO in the Gastrointestinal Tract
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In the gasfiointestinal tract, NO is synthesizd at multiple sits in the muscularis.
The NOS is localised to the myenteric plexus and newonal processes of the circular
smooth muscle layer. NO mediats itr action via the nonadrenogic noncholine'rgic
(NAl.lC) system It causes relaxation of the longitudinal and circular smooth muscls
of the lower oesophagus, stomacb, duodenrum, small intstine and internal anal
sphincter (Strk L99z).
The stimulafion of NANIC nerves leads to the release of neurotransmitters which
stimuld€ the production of NO within gas;trointestinal smooth muscles. Thenefore,
NO is considered to be a secondary messenger. NO could be stord as stable
prwuso$ called "nitrosointermediat6", which are released by nenve stimulation or
by synthsis fi a pace in line with release, thus avoiding the need for storage. Both
mchanisms could be operdive depending on the site and t1rye of pttysiological
response. Ongoing release of NO may be the preferrd mr;hanism in sphincters or
smooth muscles with active tone, while it is not needed in the ileum ad jejunum
smooth muscles with prdominmtly phasic activity (Stark 1992).
NO is one fartor of mmy in maintaining the integrity of the mucosal barrier. The
role that NO plays in mucosal blood flow (it increass it), and the interaction with
prostaglandin and NA}.{C, may indicate tttd NO is an important factor in the
physiology of mucosal protection (Stark 19T2, Salnnan 1995, Wallace 2000). The
source of NO within the mucosa could be the vascular endotheliur4 epithelial cells,
white cells, or neurons. It is the balmce betweenr vasodilatory zubstmcs (NO) and
vasoconstricton (thromboxane and endothelin-l) which may affect the mucosal blood
flow, its inteslty and defences (Chmg 2005). Imbalalrce betwen these substmces
may lead to nnrcosal protwtion or injury, depending on the prevailing substmcos.
Therefore, inhibition of NO production may cause mucosal haemorrhage, ulceration
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and loss of integrity, while the applicdion of NO donors such as nitoprusside
protects the mucosa (Payne 1993, Fink 2003). In endotoxaemiq there is a release of a
large number of vasoactive medidors, which cam cornpromise the intestinal mucosa; a
problenn worsened by stimulating the release of oxygen radicals such as superoxide
anions. The formation and release of NO maimains mucosal microvascular integrity
and protects against the harnrfirl effec'ts of enrdotoxic shock NO is a vasodilator md
adi-oxidant. It int€racts with the superoxide mioq forming a less toxic species
(antioxidant effect), and inhibits propagption of endotoxic-inducd damage by
inhibiting neutrophil adhesion and migration (Crouser 2000, Stark l9y2).
NO in the Liver
NO mediates changs in the hepatic blood flow and will influenrce the ove,rall
function of the liven. Unds normal conditions, eNoS-genenated NO is orpressd to
maintain normal hepdic blood circulAion. However, during liver injury such as
sepsis, cirrhosis, or ischaemia repefirsion injury, NO is produced in large amounts
due to up-regulation of iNOS (Kudera 20M). Thene is growing evidence to support
the role of NO syrthesis in liver injury @avies 1995). The corylexity of the NO
molecule is seen within the liven e,nvironment whene NO may be cytoprotective or
cytotoxic. During endotoxinaemia and sepsis, the stimulared Iftrptrer cells up-regulate
NOS, leading to m incrse in the production of NO (Moncada 1991, Morris 1994)
(Figure 1.5). The mrount of NO production and the redox state ofthe liver det€rrdnes
the role of NO. During oxidant sfiss where there is an excessive number of fre
radicals, NO is considered to be hepatoprotectivg uihile overproduction of NO in
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normal free radicat production may produce perox5rnititg which is cytotoxic (Stark
1992 tiuo 1994, Davies 1995, Beckman 1996, Chen 2003).
EndotoxinVcytokines
Kupffer cells
Hepatocyte
Stimulard
Ffuure 1.5: NO in llver dur{ng repsis.
Increased production of NO is seen in Cirrhosis of the liver, md has a numben of
clinical consequences. NO overproduction causes systemic vasodilatation and
hpodynamic circulation, which contributes to formalion of decreased protein
synthesis, asciteq oedema and portal hlpotension (Turkay 20A4, Stfik1992, Davies
1995).
Summary
Endothelial cell dysfrurction is central to various pathologicat procsss. It reduces
the bioavailability of NO by decreasing NO production, increasing NO degraddion or
I
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both. NO and endothelial cell dysfunction could be one of many mechanisms
contributing to the development and progression of pathological conditions (Figure
1.6). The physiological role ofNO in many organs has been established, but its role in
the pathophysiology of diseases is yet to be fully elucidated'
^_/,Ils.p"' 14 /
Irsnsr lry/jiE
Figure 1.6: Diverce role of NO ln Pathological conditionr @avier 1995).
Mcrocirculatory
Dysfirnction
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Renal Transplantation
Historv of Orsan Transolantation
The first experimenrtal animal renal fiansplart was performd by Ullmat n lWz
when he ralrsplatred a kidney to a dog neck (Ullmur L9O2). But it was Jaboulay who
first transplantd goat's and pig's kidneys into humars in 1906 (Jaboulay 1906)' It
was not until 1933 tlrat Voronoy performd the first renal tansplmt from a htrman
donor. Although he performed s€ven more trmsplarts betwe€n 1933 md 1949, all
failed due to mismatch (Voronoy 1936). Hufoagel, Hume md Landsteiner in Boston
achieved tansient renal firnction, but their success was limited by immunological
barrien. The lack of understanding of the pdhophrysiology of the irunrme response in
transpladation was the main cause of loss of the transplamed organ. Pet€r Medawar
was the fint to documot the immunological nature of rejwtion and tolermces. At
first m attempt was made to corflrol rejection by using total body inadiation before
the beginning of phamracologcal irnmunosuppression Calne introduced 6-
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mercaptopurine A to prolong canine remal tansplants md Zukounki introducd the
use of corticosteroid based on its anti-inflanrmdory etrect. Between 1966 and 1978'
azatSioprine and corticosteroids formed fte basis of immnosuppression in renal
tansplantation ln '!,979, Calne infioduced cyclosporine A' a fungal metabolite, as a
new immunosupressive agent. This resulted in a significant increase in the rde of
graft suvival (Calne 1979, Sendalg5). CsA and tacrolimus formed the comerstone
of immunosuppressive therapy, and improved the survival rate of solid organ
transplarfs by l5-20o/o. The one-year survival ratc for renal altograffs from living and
cadaveric donors are >93o/o nd >87o/o respectively. The half-life of renal allograffs
has improved from 12.7 ta 21.6 yors in live donated renral allograft trmsplarfs, ad
from 7.9 to 13.8 years for cadaveric allograffs Gtariharrm 2005). The availabiltty and
judicious use of vrious immunosupprssarts, better understanding of acute rejection,
improved re{rieval and prcenvation of orgas' bett€r orgm presenvatiorl
improvement in sgrgiel techniquc and arti-infwtious therapy all contibuted to
recent improvernen6 in remal trmspladation (Srf,harilhiran 1994, Mdas 2001,
Oberholzer 2004, Orsenri go 2O04,Lee 2005, llaz'2n2005).
HLA Ilfiatching and Cross"Matchine
The genes oncoding ttre HLA antigens re locded on the short rnr of clromosome
6. HLA-A B and C antigems are called class I and are displayed on all nucleated cells
md pldelets (Figure 2.1). HLA-DR, DP and DQ mtigens, class II, are expressed on
B-cells, monocytes-macrophages and dendritic cells. T-cells and non-llm.phoid cells
4A
(such as renal tubular epithelial cells) display class II proteins only when activated by
cytokines (Suthanthiran 1994).
Clalr lll
n m70 kb
Figure 2.1: Short arn of chromocome 6 (adapted firom Ndwe Revlcws Genetls 201}B; 9' SlGS2q.
The matching has clinical benefits. The onoyear graft survival rate was 94o/o tn
recipients with HlA-identical kidneys matched for two haplotlpes, while it is 89%
for one haplotype matching. The Collaborative Transplant Study (CTS) demonstated
that the graft-survival rate of HlA-identical recipients is superior to ttnt of gpaffs
matched for one haplotype (Oplez 1992). The estimated halfJives of matched kidneys
are 26.9 years compared to the 12.2 years of those that matched for one haplotype
(Suthanthiranlgg4, Oplez 1992). The one-year graft'survival rate of matched kidneys
is 88% compared to 79o/o in mismatched allografts, and the estimated halfJife of
HlA-matched grafu was 17 .3o/o compared to 7.8o/o in mismatched allografts
(Takemoto 1992). The HLA-matched alloggafts have a better graft survival rate, with
longer cold ischaemic time when compared with mismatched allografts and a short
cold ischaemic time. Allograffs matched for four or more HLA antigens have a better
outcome than those with fewer than four matches. The matching of HLA Ar B and
DR has been shown to be beneficial to the graft survival rate, while this is less so for
HLA-C and DQ; based on this, some policies make it mandatory to allow no
mismatches in the HLA A B and D& which is justified by the positive results
ouflined above (Cicpiarelli l99l).
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Renal transplantdion is associatd wittl increased orpression of HLA class tr on the
tubular epithelial cells and endothetium bV day five post tmsplmt. This is an
indication of graft rejection (Louffi 1991). Down-regulation of MHc class tr by
monoclonal antibodies is associdd with prolonged gaft survival. The monoclonal
mibodies also up-regulate iNOS (in the macrophages) and insease nifate
production This production increases on day five post renal and liver trmsplanta;tion
and increases siguificantly during acute rejotion (Weight lq9q'
During renal fimsplantation, a numbe,r of eve,lrts inevitably take place which
precipitate endothelial cell ir{ury: up-rqulation ofNOS ard production ofNO' Thse
events occur from the time of retieval and for the life of the organ or the rectpienf.
The kidney is subjected to wum ischaemia in live donaion or cold ischaemia in
cadaveric donation during organ refieval followod by trosplanrtation surgery.
Vascularisation of the tansplant€d organ induces ischaemia reperfision injury.
Following surgery, acute rejection and opporhnistic infwtion are the main post-
transplant complications. These evonts may occur individually or together, and one
may lead to another or facilitate its happening. In addition, thce events may favour
rejection episode.
The events afuing the narsplamd kidney firing organ transplmtation may
induce iNOS up-reuldion and NO productioq an oxiddive sfiess state and other
cellular events including clokine release and orpression of adhesion moleculs and
MHC artigens @ulHey lgg4, Cdttqn lW4). The up-regulafiion of NOS and the
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production of NO may occur with every event and may contibutg directly or
indirectly, to each event. The everfrs may also favour rejection episode, since the
released fbctors (such as cytokines) that play a part during acute rejection can up-
regulate NOS and increse the production of NO (Dwlin 1994). The induction of
iNOS and NO production dgring thse eveffs are potentially defiimetrtal to the graft
survival (Salahudeen 1996).
Both isoforms of NOS odst in the recipieirt md in the donor kidney and ftey have
different effects on the tra6plantd organ- The effects of NOS md NO in renal
transplantation depend on the tlpe of the activated NOS, amornt ofNO produced ard
the rdox state of the microenriveroment.
The effects of cl.{OS-generraed NO ane differenrt from the effects of tr'IOS-
generatd NO. Native cNOS and cNOS-generated NO has a protective property
during pattrological conditionso and iS loss may prwipitate hlpertension and allo-
arteriosclerosis (Vos 20A).
iNOS is ooconstitutively''orpressd in the tmsplmted kidney's tubules, glome'ruli,
and aterio (Mttson 20@, Albrwlrt 2000). h rat hdneys, iNOS Enists as
macrophage NOS and vascular smooth muscle cell NOS (Cattell 1994, Agarwal L996,
Suarki 2W4r. Constitutively expressed iNOS is only up-regulatd during
inflammation or acute rejection. iNOS is also up-regulatd in the invasive
inflammatory cells which are the recipied-doived activded macrophages tha
infiltrafe the tansplanted orgalr during acute rqiection The delete'rious effecb of
recipied-derived-iNOs would overshadow the beneficial effecB of donordenived-
iNOS found in the resident parenrchymal cells of the renal allograft (Vos 20&[, Jole
2W2).The deleterious effects of iNOS modulde and promote rejection, md therefore
inhibition of recipient'derived il{OS whic,h is expressed on the infiltating
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macrophages in the kidney gfaft and could protect the tansplanted kidney from the
infiltrating macroplrages thd cause remal tansplart rqiury (Albreclrt 2000). The
function of NOS within the allograft is diverse: it is cytoprotective when it acts as an
No-producing enzyme, while it is cytotoxic when acting as a peroxynitrite-producing
enzyme. fire biological effect of NOS is not only influorcd by the radiel species it
release, but also by the antioxidant capacrty of the cellular microenvironment md
ROS production (Joles z}AD.The bioavailability of NO is critically depemdent on the
sgfficient dioxidant capacity of the microenvironment. When the antioxidant
capacity is insufficient, the reaction ofNO and Oz- and the formation of poox5mitr*e
will rsult. Howev€r, if the antioxidant capaclty is sufficienf, NO production is
beneficial (Jols 2W2). The site of this oxidative strss is the activated macrophagc
ttr* infilfate the graft. They up-regulde iNOS and activate NADP(I{) oxidase, which
producs NO md e- (Crrimm 1999). Massive production of ROS specic also
influencs the availabiliry of NO. ROS increases degradaion of NO and reduces NO
bioavailability. The end rmult of reducd NO bioavailability is endothelial
dysfirnction and leukocyte recruitnent, hence providing a key eleme,lrt for rejection
ROS can also reduce NO production by inhibiting the activity of NOS (Mdord
1985). Deficienrcy of the NOS substate (L-rginine or co-factor BH+l may alter the
function ofNOS and ROS production The low supply or availability of L-arginine or
BHa will cause 'T.{OS uncouplingl', where NOS will produce supooxide instead of
NO (Vos 2W4Xa 1996). The reponses of NOS to subsfiale deficie,ncy vary: eNOS
depends more on L-arginine binding; whereas iNOS depends more on BH+ binding.
Ttrerefore, uncoupld eNOS would gsnerate a large amoud of Oz- while urcoupled
.,{OS would generate alage anrourf of pooxlmifite. NOS uncoupling is associated
with early acute rejection (tluisman 2W2).
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The effgcb of ROS are firther potentiatd by the decrease in the mtioxidm
capacity of the transplanted kidney (MacMllan-Crow 1996). The enzymdic activity
of e,lrdogenous anrtioxidants such as cdalase, glutathione peroxidase md superoxide
dismutase is low. Sgpenoxide dismutase is one enzyme found to be inactive during
acute rejectioq and as a result an increse is seen in the levels of Oz- and ONOO-
(Vos 2004).
During human renal rejection, the inflammdory and non-inflanrmatory cells in the
renral allograft produce ROS which activate the tanscription factor NF- KB, and in its
tum it up-regul*es iNOS in the intenstitiunr, the glomeruli and the invasive cells
infilfiating the graft. The deleterious effects of luge arnounts of iNoS-gener*ed No
by the invasive cells infiltrating the gfaft are morc importam than the beneficial NO
produced by the native cells and inhibition of all isoforms of NOS, reulting in a loss
of beneficial cNOS-generdd NO, which outweighs the beneficial effecm of
inhibition of iNOS. During acgte rejection, the incrased iNOS expression 4pears to
be deleterious, uihile in chronic rejection the iI.{OS uprqulation is baeficial md
compensatory (Jolc zEl).Inhibition of NO production from all NOS can decrease
the charcgs of renal graft survival by causing the loss of protection against ischaennia
or by aggravating the allo-irnmune rsponse (Vos 20M).
fire renral rqiury cagsed by acute rejetion involves the endothelium, leukocytes,
cytokines, adhsion molecules, NF-KB, NO and NOS (Figure 2.2). Nl tlrse factors
inter-relate. Endothelial cells are the first cells to be affected and are the main target
of the inflarmratory proce6s. Ttre modificatiors of the normal biological finctions of
the endothelium, such as vasculr tong coaguldion and inflmrmdion coffiol l€d to
acute rejection (Castillo 196). Endothelial injury is associated with recnritment
adhesion and erffavasation of leukocytes, which are assisted by adhcion moleculs
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(Vos 2002). NF-KB has a diverse role: it recruits leukocytes, activates cytokines and
free radicals, and upregulates iNOS. It also up-regulates MHC-[ expression'
Therefore, NF{6g enhances graft immrnogenicrty and promotes acute rejection
(Baeuerle lgg7).Interctingly, NO tends to inhibit NF-rcB (De Caterina 1995) G 2'2)'
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NO in Acute Reiection
Acute rejection creates a stress situdion in a stable environmed, subjecting normal
living cells to an inflammatory process. The living cells rqct by exprssing inducible
enz5nnes ard mediators md the influnmaory proc€ss is a complor, tightly regulated
sequence of evenfs, with initial production of pro-inflamrnatory mediators that recruit
inflammatory cells. A balance betwe€n def€nsive or offensive factors would
determine the outcome of the process: progression or reolution"
Acute rejection is a complen immunological proc€ss involving both cellular and
humoral conponents of the immune systenL md it depends on the coordinated
activation of alloreactive T-cells and antigen prcenting cells (APC) (Peld 2003).
Acute rejection is a T-cell dependmt process causing the desfuction of the aflograft,
which is orchesrated by the release of cytokines, cell-to-cell interaction md the
asserrbly of lymphocyte (cD4+ T-cells, cD8+ cytotoxic T-cells, antibody-forming
B-cells and leukorytes) (Suthmthirat 1994).
The incompatibility of antigens (MHC) betwe€n the donor md the recipiem of a
graft leads to m immune respome agpinst the graft. The passengsr leucocytes migr*e
rapidly out of the tissue following transplantafioq traveling to the recipient lymphoid
organ where they are able to interact with and stimulate tlrc host's immune responte.
These passeilrger leucocyte rapidly mature into mtigen presenting cells (APC) with
the ability to stimulate T-lynphocytc. The APC orpresses major histocompdibility
complor (MIC) on its surface (Krensky 1990). A foreign protein then embeds itself
in the MHC groove; this is recognised by T-cells forming T-cell-mtigen recognition
complo<. T-cells may recognise the anrtigen directly or following processing by the
APC. The T-cells oxpress CD4 md CD8 proteins that combine with HLA class tr and
class I, respectively, which is exprcsed on the APC or the renal allograft. The T-cell-
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antigen rcognition complor stimutats the intrace[ular protein tyrosine kinase, u&ich
increass the activation and expression of genes cenfial to tho T-cell gfowth.
Interleukin-2 is secreted by the activdd T-cells. There is a proliferdion of autocrine
T-cells arising from the binding of IL-2toIL-Z r€c€,ptors on the T-cells. IL-2 triggers
the activtion of tyrosine hnase, leading to the orprcsion of sevenal DNA binding
proteins (c-juf c-fos, c-myc) md to the progrosion of the cetl cycle. The outcome of
this cytokine production is the emergence of mtigen-specific, graft-infiltrating
dgsfiuctive T-cells (Suthanthiran 1994, Storm 2000). Cytokin6 also cause the
activation of othe,r inflmmatory cells (e.g. macrophage), B-cells (producing mti-
donor mibodis) and up-regulation of the expression of HLA on the graft cells and
ApC (Suthantfuiran 1994, Storrr 2000). Calcineurin prticipates in siglul transdugtion
md blocks it by cyclosporing while tacrolimus 4pears to be central to
immnnosuppression activity (O' Keefe 1992) -
While donor leucocytc en migr*e into the host lymphoid orgars, the recipieff
leucocyte migrate into the gfaft. The activafed T-cells are ablo to recruit md activde
other cells. They do so by producing cytokines, which direct tlre proliferation and
ditrerentiation of effector cells. IFN-1 ard interleukins are partiorlarly involved in the
generafion of activafed marrophages. During the process of acute rejwtiorU the remal
allograft is infiltrated by the activated macrophages; in addition to forming part of the
immune response, they also show an incteased orprcsion of iNOS, leading to
production of NO (Vos 20M, Dwlin lgg4). The preence of iNOS is usually
associatd with a sustained ned for large unounts of NO. This ned is usually
associatd with cytotoicity. Although the mechanism of NO production in acute
rejection is clear, it is rrrclear what role it plays. Immuologically-released NO from
endotheliat cells or rnacrophages bring about increased blood flow, hnotension'
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modulation of leukocytes (Suzuki 1991) platelets md other immunological reactions
(Radomski 1990).
The discov€ry thaf NOS-producd NO by monocytes-macrophage lineage in
response to inflammatory cytokines (IL-l, TNF, IFN-y) pronptd Jan M. Langrehr
amd Rosemary A. Hoffinan to investigate the significmce ofNO synthesis during the
courise of imnune response to alloamigens ard whether it has possible
immnnomodulating effect on allograffs (Langrebn 1992). They demonsfrated that NO
production in rd md mouse spl@ocyte MLR promoted a profound inhibitory effect
on cytotoxic T-tymphocyte (CTL) induction (Langrehr 1992, Shiraishi 1995). When
N-monomethyl-L-arginine (NMA), a competitive inhibitor of oxidafe L-arginine
metabolism, was added to the cultures, the nitrite/nitate levels decreased markedly,
resulting in antigen-specific prolifoation and CTL induction (Langrelu 1991). Based
onthis, they looked at whetherNO production could be shown in an in-vivo allograft
system- To do ttris tlrey used a sponge matrix allogaft, injwted it with syngafc or
allograft splenocytes and analysd the sgrrounding fluids for the tlpe of cells
infiltrating the sponge, in vivo NO production and the inte,ractions betw€n the
infiltrating cells and the ongoing NO synthesis. There was an early increase in the
number of macrophages in both syngenic and allogenic sponge gaffs by days six and
eight aftsr grafting in an allogenic compared with a Engenic graft. The sponge fluid
malysis showed highen NO2-NO3- levels in the allogBnic graft on days four, six md
eight aftsr gafting conpared with the syngenic graft. The culttrd md harvsted
graft-infiltrding-cells wene primarily made up of macrophages, which produce
significantly more NO. They produce more NO when cultured with L-arginine. The
effects of NO on the fipction of the infiltraning rnacrophagc were evidenrt when the
cells were cultured in the presence and absoce of N-metlyl-L-arginine (NMA)'
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When NO production was inhibited by NMA, the allograft-infiltrating cells were
cytotoxic. In the absence of NMA high NO production was associafied with the
failure of allogfaft-infiltrafing cells to show cytolytic firnction The conclusion was
thd there was a significmtly higher nifiite/nifiate level in the allogenric gaft sponge
fluid at day six aften grafting ufuich correlates with the point in time where thene is
evidenrce of alloreactivity - this is when the donor-spwific cytotoxic T-lymphocytes
(CTL) firnction was first detected. Allogfaft resporses are accompanied by NO
production trat is medided by rnacroptragc, which are the main gfaft-infiltating
cells md the m{or sogrce for the inducible NOS ad NO production Re-e;rposure of
the activafed macrophage cells to the specific donor allo-ailigsn rsulted in a surge of
NO qmthesis; thereforg the magnitr,rde of the immune rsponse with alloantigeneic
stimuldion correlated well with the amount of NO produced. NO may also lead to
inhibition of T-cell proliferdion, therefore down-regulating the immune response.
Howover, NO production is limited by the availability of the substrde (L-arginine)
(Langrebr 1993). Lmgrebn et al hlpothesized that cytokines produced by allo-
asrivated T-cells initide the No pathway in the graft-infiltrdd-macrophages. The
NO in tum inhibits lyrnphocyte proliferation and the development of allo-sensitivity.
Therefore, macrophagc play a cental role in both initiating the allo-immune
response (procesing the antigen, presenting it to \mphocytes and secreting II-l) md
inhibiting the response Oy secreting aginase to dwrease aginine levels) and by
using arginine to produce immrnro-modulatory substmces such as NO (Figure 2'3)
(Latgrettr l99l).
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Frgure 2.3: NO syntheris during allo-immune relponse. Il[acrophage p_rctentc alloantigen to
tymphocyte which secr€tes IL-i and INT. II\F stimulatc macrophage NO, resulting in inhibition
ortynpnocyte proliferation. NMA (N-methyl-L-arginine) (copied from Langrehr 1993).
Worral suggested that the net role of NO in allogfaft transplants is to promote
rejection. NO can lead to up-regulation of class II m4ior histo-compatibility (MHC)
complex or increase local production of cytokines, thereby increasing allogfaft
alloantigenicity (Wonall I 995).
A furlher experiment was conducted by Langrehr to determine whether NO
production is associated with organ allograft rejection and graft-versus-host disease
(GVI{D) in vivo, and whether NO could be a marker for this immune response. The
end-products of NO (nitrite/nitrAe) were measured in untreated and
immunosuppressed rats receiving liver, heart, small bowel, skin' sponge matix and
bone marrow/spleen cell allograffs (Langrehr 1992). Recipients with organ allografu
who developed acute rejection had a significantly high level of serum nitrite/nitrate.
However, recipients with syngenic grafu and those immunosuppressed with FK506 or
CsA had normal serum nitrite/nitrate levels. Recipients with skin grafts and sponge
+ Proliferation
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mtrix grafts did not show cbanges in the level of senrm nifite/nifarc drning the
rejection process. Ttris experirnenrt showd for the first time thaf there is an inqrease in
NO production dtging the rejection of a vascularized organ (Langrehr 1992). This was
a significarrt finding by Langfehr, md linked NO production to acute rejection and
therefore suggpsted the possibillty of using NO as a diagnostic test in solid organ
frmsplarta;tion
Shirashi reported m increase in NO production dtring the early stages of acute
rejection in rat lung a[ograft transplants. He suggwted that serum nitrite and nitte
cm serve as an early marker for acute rejection (Shiraishi 195). In pancre*ic
fiansplarfis in rats, Tanaka formd a rise in serun nirate level on the fifttt day post
trmsplant in allograft tansplants, but not in syngenic graffs. The elevation of NO in
ttre blood was detffted before the elevdion of the blood glucose level (Tanaka 1995).
Ohdan studied NO during acute rejection in rat liver tansplarfafiorq demonsfating
thd acute rejection in liver transpladation is associated with a rise in se'rum nitite
and nitr6e (Ohdan lg5). Lu oramined the role of NO in acute renal rejection in rat
models. By the eighth day post fiansplml all animals had severe degrees of acute
rejection. There was a rise in senrm nitrite levels from day two, which rerrained high
up to the eighh day, and also a positive correldion betrreem the level of nitrite in the
serum ard the gfaft. His final conclusion was thaf the,re was an increase of senum
nitite ealienthanthe pathological manifstation of acute rejection He zuggestd that
NO could be used as an early indicdor of acute rejection (Lu 199). Anothen study
by Suzuki measured the levels of senrm md urinary NO in rars during renal acute
rejection He found a significant rise in serum NO levels during acute rejection in
allografts when compared with isograft models, while the urinary NO was found to be
lower in allograft models (Suzuki zOM}
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In humans, Atbrec,ht used serum and uinary nitrite and nitrate as non-invasive
markers to diagnose acute rejection in renal allograft recipients. Ttre results showed a
gadual increase in serum nitrite and nitae and a significant decrease in urinary
nifite md nitate two days before the diagrrosis of acute rejwtion In cyclosporine
toxicity, senrm NO was elevde{ but this was not significant compard with
recipients with acute rejection or m uncomplicated course; howeven, urinary NO was
significantly highen compard with rwipients with acute rejection Albrecht suggwted
ttrd serial measurernent of urinary and fasting senrm NO csr be of clinical value as a
non-invasive marker in acute renal allograft rejection (Albrecht 2000). In a similr
study, Dedoglu et al looked d se,rum and urinary NO in paediafiic renal allograft
recipier$s. The results of the study showed tha sentrmNO did not chmge significanfly
during acute rojection opisodes. Ttris is because in renat fiansplants there was an intra-
renal production of NO, which contibutes largety to the quantity of NO €xcreted in
tlre urine of remal allogfaft recipients and decreases the levels of serum NO. Urinary
NO decreased by 74o/o of the baseline value during acute rejwtion During acute
rejection there is also a reduction in GFR and tubuls injury, which contribtrtes to the
diminishd udnaryNO excretion @edeoglu 1996). Takahashi measured serumnitrate
in eight renal allogfaft recipien8, and saw ar increase in sorum nitate during acute
rejection. Recipienrts receiving tactolimus have markedly reduced senrm nitate levels
in the early postoperative period when compared with those receiving cyclosporine
(Takahashi 1998). Smith measured nifiite and nitate in urine during acute rejection
and urinary tract infection in 25 renal atlogfaft trmsplant patients (ll cadaveric md
14 live). Urinary nitrate levels were highen during acute rejection, with no change in
nitrite levels, while there was an increase in the levels of nitite in udnary infection'
with no change in urinary nitrate. This is bwause bacteria converb nitate to nifrite in
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pdi€nts with UTI (Smith 1996). Bube,n also usd urinary nitric oxidefurinary
cretinine (U-NOX/U-Cr) to diagrrose actrte rejection in human recipients receiving
cadaveric kidney transplantdion He also used the same test in cyclosporine toxicity.
He concluded that U-NO/u-Cr decreases two days before acute rojectio4 but there
were no changes in U-NOX/U-Cr in cyclosporine toxicity @uben 2ml). Mtge
lookd at the NO production during acute rejection in cardiac transplant patients' He
measured urinary nitrate in the recipients, since it is nitrate that is errcreted by the
kidney. He used a single udndy test and did not interfere with the pdients' dies. He
oomined the resulf with regards to urinary nitate and urinary nitate excretion
(quotierf urinary nifiate to urinary cretinine concentation). He formd a significant
increase in urinary nitate and in udnary nitrate orcretion in acute rejection The
dge of increse in urinary nitate md in udnary nifae excretion was in keeping
with the severity of rejection However, masuring urinary nitrde orcrstion was
associafid with a wide inter- and intra-individual variatioq possibly due to dietary
variafions and immunosuppressive regims (Mtgge 1996). In healt tansplant
pdients, Pall showed an increase in senrm nitrate in acute rejection (Paul 1996). A
similar study was conducted by Worrall, who reported that there was increased NO
production during early acute rejection, and thd NO production pe'rsisted throughout
the wmodifid rejection procss in experimedal heart transplm8 (Worrall 1997)'
Silkoffmeasured the orhaled NO (eNO) in lung fimsplantdion as a non-invasive
marker. ENO is thought to increse during acute rejection but not with infection
(Silkoff 1998). Othes used NO as a marker of hrng allograft dysfunction and chronic
rejection (Gabbay 199% Fisher 1998). This furfrer supports the role of NO in acute
rejection in solid organ transplantation.
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Following the various studis providing evidence supporting the use of serum or
urinary NO in diagnosing acute rejection, othcrs exploited the role of NO in organ
tansplantation For instance, Koyama used NO to prdict the allograft outcome
following acute rejection, stating thd chronically rejwted orga$ migls produce NO
due to m ongoing lafenrt immunologic reaction Recipients with chronic rejection who
went on to lose fte allograft were found to have twice the level ofNO when compared
with recipients without chronic rejetion Thus it was concluded that senrm NO cm
predict the progress of c,hronic rejwtion and the fate of the allograft (Koyama 2@0).
Castillo's work concentrded on the role of NO in the biological mechanims during
hl,poacute vascular rejection in >renofiansplantation Gig-to-dog). ttre reportd a rise
in serum nifiite in the renal vein five minutes after perfrrsion, therefore repres€nting
an increase inNO levels in the blood coming out of the graft, while senrm nitit€ in
the remal art€,ry renrained unchanged. These two observations indicaed thar the source
of NO production is the tansplmt€d kidney and is unlikely to be of systemic origr
Thenefore, the rise in serum nitrite in the renal vein is most likely to be due to
hpenacute vascular rejection and not to surgical rqiury during the fianspladation
procedue. Castillo also fotrnd ttrat iNOS activity in the renal parenchyma afi 30
minutc post-perflrsion was gf@t€r than thd of cNOS. As a rmult of this, large
anounts of NO are produced; this is cytotoxic and not a vasodilator. Endothelins af,e
also produced and may precipitate the intsnse vasoconstiction that is seen in
hlperacute vascular rejection (Castillo 1996).
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Imrnunosupprmsive drugs have an €ffect onthe microvascular endothelium Most
immunosuppressive drugs significantly enlunce the production ofNO, withthe
exception oftacrolimus (trapp 2005). The quality and quantity of
immunosuppression modi$ endothelial firnction and lead to a dose-dependent and
orygenation-state-reldd enrdothelial activation MP md MMF induce minor dmnges
in endothelial function compared with cyclosponq raparnycin sd tacrolimus (Trapp
2005). R4urycin has also beem fornd to decrease the elrprssion of eNOS in the
endothelial cells (Chen 2006). CNI inhibits iNOS ocpresion ard reducc NO
production (tlamalAinen 2008, Trfl6n 2@3, Strstikova2$O3, Strestikova 2001,
Watarai 2004, Kim 2@3,Dawson 1993). Tacrolimus inhibits iNOS dthe
trmscriptional level inthe macrophages, urhile down+egulation of iNOS orprssion
by cyslosporin occurs post-fianscriptionally (Stetikova 2001, Chen 2006). CNI
nephrotoxicity is thougfrt to be medided by a vasconsfiictive effect arising from the
enhancd activity of vasoconstictor enrdothelin md a decrease in production of intra-
renal NO, a vasodilator (Watarai 2W4). R4amycin and mycophenrolate mofetil
(Nflvfi) also inhibitNO productionmd iNOS o<pression and decroasethe
intracellular generation of ROS (Td6n z0fl3l,Lui 2001).
Corticosteroids
Coricosteroids inhibit T-cell prolifoation and the orpression of cytokines (IL-l, tr,-
2, fr,-6,IFN-y, TNF-a). They also form a heterodimeric complor which blocks the
transcription of the IL-2 gene (Suthanthiran 1994). Corticosteroids cm iohibit both
iNOS and 6NOS ard inhibit the production of NO. Corticosteroids cm inhibit iNOS
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directly or indirectly (by induction of a protein that inhibits the enrzyme [.[OS) or
inhibit endogenous cytokine synthesis. This could be the basis of the anti-
inflammatory action of glucocorticoids (Radomski 1990, Humg 1995, Fuhua 1995)
(Table 2.1).
Azathionrine
Azattrioprine is an anti-metabolite and a derivative of mencaptopurine, and inhibits
the entire purine bioqnrthetic pathway. Azattrioprine causes inhibition of iNOS and
this is the basis of its anti-inflanmdory action Mercaptopwine has no effect on iNOS
(Moeslingerr 2006, Grishen 1994).
Calcineurin Inhibiton (CT{D
Cyclosporin blocks calcineurin (ptayrng the part of a signal fiansducer) ard hence
blocks T-cell activation and T-cell activation g€n6 (L'2,II-2 receptors, c-myg c-
fos). It is a potent inhibitor of Il-2-stimulated T-cell prolife,ration and generation of
cytotoxic T-cell lymphocytes (suthamhiran lgg4). Cyclosporin is known to inhibit
NO production (Morris 2O00, otang1999) (Table 2.1).
Tacrolimus (FK506) inhibi6 calcineurin by binding it to aheterodimeric cornplor
corsisting of FI$06 ard ar FK-binding protei4 inhibiting the phospharase activity of
the calcineurin (Srttranthiran lgg4).It also inhibit iNOS eurpresion and NO
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production QlamalAinenr 2008, Ttfl6n 2003, Strstikova2}}3, Strestikova 20Ol'
Watarai 2AM,Kim 2003, Dawson 1993) (Table 2.1)'
CNI rduces NO production by modiffing the endothelial firnction or increasing
the rate of decay of iNOS (Watarai 2}M,Ttqp 2005). Tacrolimrs hhibits iNOS at
the transcriptional level in the macrophages, while iNOS exprcsion down-regulation
by cyslosporin occurs post-trmscriptionally (Stestikova 2001, Chen 2006)' CNI
nephrotoxicity is thought to be mdiated by a vasconstrictive offect arising from the
enhmcd activity of vasoconsfiictor endothelin and a decrease in production of inta-
renal NO, a vasodildor (Watarai 2W4}
Mvconhenolrrte Mofetil (MMF|
MMF selectively inhibib the de novo pafhwary for purine bioqnthsis and is
converted into an active compound lnown as mycophenrolic acid (MPA)' MPA
inhibie the proliferdion of T- and B-lymphocytes by blocking inosine
monophosphde detrydrogenase, the rdFlimiting Efuyme for purine synthesis during
cell division MPA also inhibits the generation of cytotoxic T-cells and mtibody
production MpA has no effet on oNOS but it inhibits iNOS in a dosedepende'ff
fashion iNOS is a cofactordependent €nzyme (Table 2.1). These cofactors include
tefalrydrobiopterin (BH4), FAD, FMN md NADPH. BH4 is the rate limiting factor.
iNOS depends on BH4 biosynthesis, and MPA inhibits biosynthesis of BH4, therefore
suppressing cytokine-induced NO production (Senda 1995)'
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Sirolimus (Ranamvcin)
Sirolimus preve,lrts acute rejwtion by forming a complor with FKBPI2, and then
targets am infacellular protein called oomarunalian targpt of rqamycin" (mTOR).
mTOR is a serine-tbreonine kinase which is important in severral signal fiansduction
pathways that lead to stimulafion of TJymphocytes and othe,r non-immtne cells
following cytokine or growth factor stimuldion It thenefore inhibits the progrssion
ofthe cell cycle and interferes with the proliferdion of TJynrphocytes md othen cells.
Sirolimus inhibits NO production by inhibiting up-reguldion of iNOS at the
mRNA levels (Td6n 2003, Phan 1998) (Table 2.1).
Both r4anrycin and mycophenolate mofetil (MMF) dwrease the itracellulr
generation of ROS (Td6n 2@131, Lui 2001).
fmmrrnosupressive Drug Mechanism of Action Anticipatcd Effects
Calcineurin inhibitors
Corticosteroids
Rapamycin
Mycophenolate mofetil
Inhibit it{OS franscription
Induce eNOS tmsoiption
Inhibit eNOS activity
Inhibit iNOS tanscription
Induce eNOS trmscription
Increase eNOS activity
Inhibits
tanscription
iNos
Limits BH4 availibilitv
May limitNO production
MaylimitNO production
May limitNO production
May limitNO production
Table 2.1: Snmmary table of lnmunorupprerslve effect on NO and N(Xl (Shah 2lXl3).
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Other Post Renal Transnlrrnt Comnlications
Urinan Tract Infection
This is the most common oppornrnistic infection in renal frmsplmt recipie'ffi.
Patients with udnary tact infwtion have an elevat€d urinary nitrit€ level when
compard with healthy contols (Smith 1994).In large qumtities, NO can modulde
ttre inflamrnatory resporule. The source of NO cm be from the inflamnatory cells or
from the infected uroepithelium (Po[akovie 2OO3). The NO released by the
inflammaiory colls is bastericidal while that released by the uroepithelium is involved
in shedding the infected and damaged uroepithelium (Poljakovie 2003). During the
course of UTI, large numbers of neufiophil are recruited by cytokines (IL-6 md IL-8),
which are released by the hfected epithelial cells in the urinary fiact (Wheelen 1997).
These urinary neutophils show an incrase in the activity of iNOS: the hflammatory
rsponse promotd by iNOS is responsible for the symptoms of UTI (dysuria md
frequency). The production of large quarfities of NO md ROS ard the formdion of
pooxynitrite make iNOS bactericidal. The activity of iNOS is 43 timss high€r in
nzutophils in urine from pdients with UTI. There were no incrmses in the activity of
gNOS in the urine from pdients wittr UTI. Patients on inrmunosuppressive therapy
showd no increase in NIOS activity despite persistenrt bacterial and ftngal infection
(Wheler 1997, Smith 1994, Olsson l99S). eNOS could be responsible for m increase
in NO production in ttre first hour of urinary sepsis, urd iNOS activats four hours
after infection eNOS phosphorylafion is involved in the early response to Ll'fI, ad
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iNOS is involved in the later reporse since it requires fmscription and franslation
(Karg 20M).
Peritoneal Dialvris Peritonitis
This is one of the complications thd may occrrr in recipieds on peritoneal dialysis
post renal fiansplalrtation Its symptomolory is aMominal tenderness md pain md
infected discharge from the poitoneal fluids. It is treded by surgical reuroval of the
poitoneal cafheter. It is a local inflammatory process which involve recruituat and
e!ffavasation of ptragocitic leukocytes in the peritoneal cayity, release of cytokinc
and stimulafion md up-rquldion of iNOS, md large-scale production of NO. In
animal orpoiments, injwtion of LPS irto the poitoneal cavity is associatd with
increased systemic NO production (Olsson 1998, Kang 2004). Thereforg m increase
is anticipatd in serum NO during PD cdlrst€r p€ritonitis, as seen with other
infuions (Durmay zOW, Ni 2005, Davenport 26tgt4, Plum 1999, Choi 1998, Yag
1996, f,buma 1995).
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Chanter 3
Renal Biopsv and Non-invasive Tests Used in
Diasnosine Acute Reiection
Renal Bionsv
Renal core biopsy is the gold stadard techrique used in diagposing acute rejection
It is performed whe,never there is abnormal remal function in a renal tansplant
recipietr. In a saf,e, experienced hm4 it yields a 96.40/o adequate histological
diagnosis, nd 97o/o of recipienb are disdrarged within 48 hows, though it can be
performd as a day case procedure (tlussain 2003).I{aem*uria is the commonest
complicatioq occurring in 4o/o of recipients, ufiile l.5o/o elrcountsr major
complicatiors requiring blood tansfision or other interveutions (Tmg 2002, Hussain
2003). Sc|warz et al lookd at 2l7O renal biopsies; all were treafd as outpatienrts
using a 16- or l8-gauge needle yielding an adequate specimenr The reported
complications were gross haennaturia (3.5%o), perirenal hamatoma Q.sVo), arterio-
venous fistulae (7 3yA and a m{or complication requiring blood tmsfision (l7o).
Ttre hospitalisation rate was l.9o/o nd the four-hour recov€ry poiod post biopsy was
adequate (Schwarz 2005). Prda et al reviewed 550 renal biopsie in tansplanted and
ndive kidneys. They had 95o/o afiqrnte tissuc. The coryliation rate in the
tursplanted kidney ww 8.7%o, while the major complicdion rde in the tarsplatted
kidney ww 2.9o/o 
- 
higher than that in the native kidney QAVA. The major
complications included death and loss of tansplmted renal allograft. The minor
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complication rate in the tmsplanted kidney was 5.87o, while this was higher in the
ndive kidney biopsis @rda 2003). Fumcs lookd d,3613 biopsic and assessed
them for mqior md minor comptcations, concluding in his study thaf the benefif
outweigh the risk in roipients with stable graft function undergoing protocol biopsy,
atthougtr he admits thA they did not assess the direct benefif to the recipie'nts
(Fumess 20Ar.
Bsides complications, the othen drarrbacks of renal biopsy are:
o The need for m orperienced ulfasonogr4her
o The need for a traind doctor to pe,rfomr the procedure
o The need for an orpaienced histopdhologest
o The timerconsuming nalure ofthe procedure
r The long reporting time following the procedure
o The requirerment for hospitalisdion
o Thefrequentdelayintreaffnerf
r The high cost of the procdure
Non-invasive Tesh
Interst in non-invasive methods continues to zd;f;act attention because of the
invasive nature and tlre complications associded with renal fue-crrt biopsy; h€nce,
clinicias are heitant in recommending protocol renral biopsies unlss the're is a
strong clinical indication (Schwrz 2005). Avoiding roral biopsy means subclinical
acute rejection is being missed, which in itself could have an effest on the long-term
result ofthe renal allograft.
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Acgte rejection ignites a cascade of a complex network of cellula interactions,
cytokine release and variow gene md rel*ed surface protein (CD80, CD28, CTLA4)
up-regulation (Suthurthirar 1994). Cltokine also up-regulate the expression of
adhsion molecglc (a co-stimulator), faciliAting the function of T-cells. These
proteins are expressed in the pe,ripheral blood cells, excreted in the urine or within the
urixary cells or up-rgulded within the graft tissues. Various techniques md methods
have been developed md used to measure these proteins in bloo{ urine md gfa'ft
tissuc in ar dtunpt to understand the mechanism of acute rejection, and to be
simultmeously explored as a non-invasive metlrod to diagnose acute rejection. The
continuous advances of new technology in molcula biology have enabled us to
investigate md study the complicded procss of acute rejectio4 md the sarne new
twhnology is being used as a non-invasive method to diagnose acute rejection
Blood, tissus, urine and radiological tests have bea used in searching for an
altemative t€st to renal biopsy to diagnose acute rqiection
1. Blood
Peripheral blood is the first line of interest by rsearchers since it is easy to obtain
and readily available. Simon lookd at the 'leripheral blood" gsne expression
measurernsrt for perforin ard granzyme B using a real-time polymerase chain
reaction (PCR). During acute rejection thene is a higher transcription rat€ of perforin
and grarzym B and a decrease in their orpression by anti-rejection treatment The bet
diagnostic rsultr we,re obtaind from samplc taken on days 8-lQ with a specificity
of 9yo/o anrd a sensitivity of 82o/o for perforin, and a specificity of 87o/o and sensitivity
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of T2o/ofor granzyme B (Simon 2003). The same goup used another marker (soluble
CD30) in an attompt to predict which of those recipients would be af risk of acute
rejection (Pelzl 2003). Aquino also looked at perforin, g;anzym B and Fas ligand
duing subclinical acute rejection He concluded that there is an increase in the
ocpression of protein-encoding gBnes (which ae involved in the cytolytic ad,tack
€ainst the allograft) during subclinical acute rejwtion, confirming it as m active
immgne process potentially deleterious to reiral allografts. However, there was no
significant diffenence when compared with the results from normal functioning
allografts (Aquino 2W4).
Al@lin et at used a highdasity oligouray technique, which is a qumtitive tst to
study the expression of thousands of genes in the small tissue ofthe renal biopsy. Up-
regulation of a spwific gene tmsoipted dtning acute rejection was considered to be
significant if tanscript abrmdace increased four-fold or more relative to codrol
bropqy samplos. Of these tanscripts, only four (humar monokine induced by
interferon-gamm4 T-cell receptor active beta-chain protein, interleukin-2 stimulated
phosphoprotein, and RING4 (a tasporter involved in amigen preenrtation)) were
consistently up-regulafed in each acute rejection sample relative to at l@st two of
thre contol bropsy sampls (Alelin 2001). A flow cytometery technique was used to
quantiry production within periphoal blood mononuclear cells (PBMCs) of multiple
cytohnes. The technique is semsitive enough to detect differences but more rcqrch
needs to be done in relation to actrte rejec.tion (Magw 20M).
2. Urine
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The cellular coffent of grine may show some changes during acute rejection Urine
cytology may show an increase in the lynrphocyte count (587o) when coryard with
nantrophils (35y") during acute rejection and this ca be used as a simple diagnostic
test (Ta$omirovic 2003). The mmsuremerf of fte mRNA encoding cytotoxic proteins
(pqforin nd granrymB) in the urine cells using a polymerase chain rection (PCR)
has a good level of sensitivity and specificity and cst offer a non-invasive mems to
diagnose acute rejection (Sgthanthirm 1994). A largp number of orpressed proteins
orcreted in the urine cells were measured during acute rejection and most studies
showed gp-regulaion of proteins zuch as chemokines [CxCR]-binding chemokines,
monokinc (Mg/CXCL9), IFN-gama-inducd proteins of 10 kDa (IP-10/CXCLI0)'
IFN-inducible T-cell chemoaffiactants (I-TAC/CXCLI l), CD103, CDl03 mRNAb
adhsion molecule (sICAIVI-I, sVCAIvI-l), md cornplemeril dqfadation products
(C4d) (Ding z003,Lederer 2@3, Hu 2@4).
3. Radioloeical Tstt
Hasmodynamic changes occurring within the rejectd renal allograft cm be picked
up radiologicall5 so duplor ultrasound has been usd to diagnose acute rejection It
was reported by Kabraman that a high resistive indo< (RI) ard pulsafile indor (PD
would indicde impaired allograft function Performing duplex at a repeatd interval
may predict early and long renal dysfirnction $alramm 2W4}Quresh used an
isotopic renogram and showd thd duing renral perfirsion dr increasd uptake would
indicate acute rejectio4 advocating anrti-rejection fietueil$ (Qurshi 2005). The latest
advances in radiological twhniques have also been uss4 for instance magnetic
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rsonmce imaging (l!AI) has been usd to detenrrine the feasibility of using blood
oxygen level to differerfide befiveen acute tubular necrosis (ATN), acute rejection,
and normal fimction It was found thaf the R2t measuremenb (u/hich measure the rate
of signal loss in a spoific region and are related to the amount of deoxyhemoglobin
present) in the mdullary regions of transplatred kidneys with acute rejection wene
significantly lowe,r than those in normally finctioning transplants or trarsplants with
ATN. These rwults suggwted that marked changes in iffia-renal orygenration occur
during acute trmsplam rejection (Sadounki 2005).
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Chanter 4
Methods of Nitric Oxide Analvsis
NO analysis and measurement is achievd rsing various methods and techniques.
The advantage of an automded aralysis is a short anatysis time, and high selectivity
which avoids both false positive and false negative resul8 due to interrfering
substmcs such as phosphate ard citrae in physiological concentrations, which could
be formd in plasma and urine. Urine in particulr is a corylex sample, and removing
interfering substmcos could be associAed with the loss of a small arnount of nitate
(Green 1982).
A limitation inlrerent to all techniquc usd to measure NO production is thd they
do not discriminate between the various isoforms of NOS (eNOS, nI\OS, iNOS).
Within renal diseases, NOS orpression may vary d differerfr stages of the disease md
rhis could re,flect accordingly on the NO production and plasma nitite and nitrate
levels (Wwer 1999).
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NO is an unstable molecule and can be converted to nitite nitrate and other
intermediaries (nitosoglutathione, nitrosoalbumin md nitrosohaemoglobiq atl
converted to nitate). Nitate and nitite however, are stable molecules and cm be
used for quantitdive measuremenrt (Tsikas 2005, Tsikas 2W6). Their concerfratiom
in biological fluids are less prone to chmges causd by alterations in metabolism or
decay during sample collection or storage. It is worth noting that endogenous nifde
generation is not limited by the L-arginineNO pafhway, and therefore nitate level is
not a stedy-state situation Nitrde is an inactive metabolite urd its concerilration is
constant @aylis 1998). Nitrite concentration in humans and animals reflects
endothelial-depenrdenrt NO synthesis (Tsikas 2005).
Basd on an automated analysis syst€m, nitrite and ninae conce,lrtation we're
measured in various biological fluids (thousards of samples of human and rat urine,
human saliva and plasma) Clable 4.1) (Green 1982).
However, it is worth noting that nifite and nitrate are measured by various tecbniquc
and the outcome may vary ged,ly Oabb a.2).
Biological fluid Nitrate (NG- ) pmol Nitrite (NOr- ) pmol
Urine
Saliva
Plasma
Gastric juice
Milk
250-20ffi
200 
- 
600
15-60
s0-85
20 -30
Not det€mind
30-2to
Notdstermind
0.40 
- 
60
NotDeterrdned
Table 4.1:Ihe range of nlffite and nltmte concentratlon ln h.rnans.
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Method Nitrate Nitrite NO2+NO3 Referpnce
Batchmethds:
Griess
Fluoromefry
Instrumentoil Methods
Griess (anrtomated)
GC-MS
HPLC.I.Iv
czE
HPLC.tIV
4- 45
t5-60
38
26
52
1- 13
N.R
1.8
1.3
3.3
34
l.l
Moshage et al (143)
ll'{ertuagetaI(132)
Green etal(126)
Tsikas 6,al(127)
Wennmalam et d (131)
Ueda et at (1,1.6)
El Menvawi et al (133)
Table 4. 2: Varlous nethods of NO onalysis. llR: Not Reported; GC-Mfl: Gas Chromatography'
lfiass Spoctrometry EPLC-IIV: Hlgh Perfomanco Liquid Ctromatography-IlltraViole{ CZE:
Capillary Zone Elestr ophenir.
Nifiite and nitrate in the body fluids originate from dietary intake inhaldion of NO
(minor source) md enrdogenrous NO grnthesis.
Dietary nitrate and nitrite is mainly nihaf€ found in green vegetable and'in some
water, ard nitite is used as a preservdive in proc€ssed foods. Therefore, nitrite and
nitrat€ intake is variable between individuals. The excretion of oral nitrate is via
faeces (14 yA and urine (6e70 YA, nd the rest Q9-39 7o) is lost within the body
througfu bacterial degradtion ofNOx in the lower gasfoidestinal fract @aylis 1998).
Nitrate is actively tansported into the salivary glmd md is then secretd in saliva"
Salivary nitrate is conve,rted into nitite by micro-organimr on the tongug and once it
reachs the stomach some of the nifite is converted to NO wittrin the acidic
environme,lrt. The NOx that passs through the stomach may be reabsorbed ido the
gastointctinal tact (entoo-salivary cycling), lost in the faeces or degradd by
bacte,ria NOx is also lost via sweat and exhaled air (Baylis 1998, Blum 1998,
Schmidt 1999).
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Urinary nitr6e cannot be usd as a quatrittive measuremsrt of endogenrous NOx
production in uncontolled NOx dietary intake @aylis 1993). If the oral irfake of
NOx is high" the urinary NOx excretion is usually less than the intake; therefore the
net NOx spthesis cannot be demonsfidd (Green lgsl). To achieve a memingful
and accurate udnary NOx mesure,men! samplc must be obtained unden controlled
low nitrate irrake. In the case of blood samples, it is recommended that the patiem
should fast for 12 houn prior to the sample being taken, arrd the tSPlu reflect
mainly enrdogenous NO production If blood sarrplc are collected randomly without
dietary restictioq the plasma nitrate measurem€nt could be vaiable. Plasma nitrde
pels 45 minutes after oral irfake and remains hig! for seiveral hours. However,
balance is achievd within 24to  Shours after alow-nitate diet, md urine and blood
sarnple can then be collested. It would take four to five half-lives for nitat'e to reach
steady-state @aylis I 998).
The other facton ttrd may have a impact on urindy or plasma nitrde levels are
afinospheric poltdioq heavy exercisg phosphale, citratg nitroso-containing
substmces, acid pH and Vitamin C (Green lg82). Heavy orencise caus6 increased
NO generation and NOx excretion via swet; therefore activities should be limited
before obtaining a sample, to obtain a tnre estimate of basal production (Shen 195).
I)rug the,rapy such as isosorbide dinitat€ may also affec't plasma NO, particularly in
NO donors, however it cortrributes little to the NOx levels (Baylis 198).
Thus, the soqrces of nitrate and nitrite can be either endogenous or oogenous.
Nitate md nifiite resulg endogenously from a breakdown of NO, and orogenously
from diet. Therefore, measrre,m€nt of plasma nitrite and nitde cmnot differer$ide
the source of nifiite and nitrare; hence, intake of nitrite and nifiate must be corffolled
when using nitrite and nitate to measure NO production (Schmidt 199).
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ln humans, NO oxidizes in the plasma to nitrite:nifde in a rdio of 1:5' However,
this depads on the oxygenation of red cells GIb). In venous bloo4 NO otists more as
nitite because of lower levels of oxygem*iorL and it is formd by auloxidation in the
plasma In art€rial bloo4 NO odsts more as nitrate and it is oxidised by OxyHb'
Oxidation by OryHb is 450 times fasten than autoxidation Furthermore, oxiddion of
nitite to nitrate oocurs in red cells. Nitite and nitrAe are stable for 60 minutss if
blood samplc re stored on ice and plasma incubared d,37"c (Tsikas 20a6, Tsikas
2005), ard bottr ae stable for seve,ral morflu if stored d'lEoc (wen[rmalm 1993).
The change in the levels of endogenous endothelial NO production aising from
cags6 such as pharmacological drugs are best reflected by serum nitrite, which can be
used as quantitative indices of NO productioq while urinary nitrate is a more reliable
indication of 'lrhole body No synthesis" under basal or sfss situdions (Tsikas
2006, Tsikas 2005) (Figure 4.1). If the intake of No is incresed by No inhalation
there is an associated inoroase inthe levels of nitrate md Mettlb, but not in the level
of nitite. The intraled NO is takem up by the rd cells and conventd to nitrate and
MetHb. This is the major metabolic pdhway for endogoously-formed NO (Tsikas
2@5, Wennmalm 1993). Incubatrng arterialised btood with nifiite results in dose
depodent increses in nitrde and MstHb formdioq and incubding nitite wittt
ve,lrous blood incroases the formation of nitrate, MefiIb and nitosohae'moglobin
(I{bNO), wtrich is converted to nifiate (Wennmalm 1992, Tsikas 2005).
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Reaboorption
I
I
Figure 4.1: NO absorytion, r€cretion and metabolicm (copied from Baylis 1998).
Measurement of plasma NOx reflects the level of renal function, plasma volume
and indirect index of systemic NOx production Measurement of urinary NOx is
uninformative or not a true quantitative indicator of NO production, due to a number
ofreasons:
l. The proximal tubule contributes to the plasma nitate by its substantial
tubular reabsorption of NOx; therefore a urinary sample is not informative
about either renal or total systemic NO production.
2, Acute changes in the urinary NOx could be due to epithelial handling of
NOx or NO generation (Suto 1995).
3. NOx can be exerted by other routes, faeces, exhaled air (Westfelt 1995)'
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4. NO cm be onvertd into othen end-products.
5. NOx cmnot be eliminded completely fromthe diet @aylis 198).
The aclte changs in urinary er(cretion of nitrite and nitate do not necessarily
predict renal vascular NO production. Under normal conditions nifiite and nitrate are
e*ensively reabsorbed md generated by the proximal tubule epithelial cells (Suto
1ee5).
The endothelial cells, neuronal sources' epithelial tissus or all these in
combination generate NO in very small amorm$ with a large impact on the
hae,modyramics (haemodynamically active NO), but this does not coffiibute a
significant anount to the totat NOx levol. Increased production of haemodynamically
active NO is trivial and not detectable in the circulafing systemic concenfation of
NO. The increase in the total body NOx generdion does not reflect biologically active
NO, but it reflecb m increase in the production of NO during pathological states such
as immunological stimulation (Bayhs 1998, zutharthiran 1994)'
NO end-products can be masurd by various methods wfuich include:
1 . Colorimeteric spectrophotometric
2. Lllfiaviolot sPwtoPhotometric
3. Fluorometric assays
4. Chqniluminesc€noe
5. High Performmce Liquid Chromatography (IfLC)
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6. Capillary EleclroPhoresis (CE)
7. Gas Ctnomarography (GC)
8. Gas Chromatography-Mass Specfiomertry (GC-MS)
Each method gives a difrenent serum and urinary nifiite and nifrate value in
humans. The reasons forthis coutd be dietary imake methodological proble'ms orpre-
analybcal factors. The pre-malytical factors depend on the NO end-products
measured. Although nitrite and nitrae are stable for 60 minutes in blood samples
when placd on ice, and stable in plasma when stored a!37o0, nitite has a short life
in whole blood samples since it is oxidised to nitde. Laboratory materials (pipettes'
pipette tips, monovett6) may cortain nitrite and nitde. AnticoagUlants used in blood
sample monovettes such as EDTA atso contain nitrite and nitate (Tsikas 2005).
The principle behind measuring nitit€ md nitrate in serum md urine is based on
two tlpc of reactio4 derivatization reactions md diazotization reactions'
Derivatization Rsctions
In a derivatizalionreactiorU nitrite or nitale is converted to derivativs that can
absorb ligbt in the ultaviolet or fluorescent rmge. GC, CrC-MS rod
chemiluminescence are based on derivatization reactions. In GC md CC-MS, volatile
ad th€rmally stable derivdives are generatd. CIC-MS is a cormronly-used tqt to
ddermine nitite and nitrate based on two derivatization reac-tions:
First reaction: nitration raction where nifiite is oxidised to nitrate and then forms a
nitroaromatic derivative. The drawbacks ofnitration reaction are:
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1. In the preseilrce of high levels of nitrate zuch as in plasm4 serum and urine,
nifiit€ cannot be accurately determined.
2.Derivafizfron reactions cannot measure nitite and nitate simultaneously.
Smond reaction: nitite reacts with pentafluorobenzyl bromide (PFB Bromide) to
formnitro-pFB and then nit*e reacts wift PFB to form nitric acid ster PFB: This is
the sole raction, which can measure both nitite and nitde simultaneously'
Furthermore, samples do not need to be pretreded (Tsikas 2W6, Tsikas 2005)'
Diamtization Reactions
In diazotization reactior! sulfanilic acid reacb with nifiite to form a diazonium
cdion, which reacts with o-naphtrylamine to form a diazo compound tbA absorbs
light aomd 540 nnr This recton is specific for nitite. This method canr be carried
out in bach or automded assays. This is the basis of the Griess reaction. There are a
few drawbacls associated with diazotiz*ion reactions:
l. Unspcificity of the rsults in bdch assays, hence automdd tqts are more
reliable boause they eliminde interfering substances'
2. Incomplete reduction of ninate to nifiite bythe nitate rductase.
3. Reduction of nit*e to nitite may vary from sample to sample.
4. Calibration curvs are usd to quurtitatively determine nitite and nitrate in
the smple. Incomplete and variable reduction ofninate to nitite may result in
different calibr4ion curves; thenefore qumtification methods based on
calibration curves may give different valus.
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Greiss Reaction
In lg79, Greiss described the diazotiation of an aryl amine by nitrite and coupling
of the product to form an azochromophore (Green 1982). This assay determines NO
based on the emymatic conversion of nitrate to nitrite by nitrate reductase. The
reaction is followed by a colorimetric detection of nitite as an azo dye product of the
Griess reaction. The Griess reaction is based on the two-step diazonzatjon reaction in
which acidified NO2- produces a nitosating agent which reacts with sulfanilic acid to
produce the diazonium ion This ion is then coupled to N-(l-naphthyl)
ethylenediamine to form the chromophoric azo-derivative which absorbs light at 540
nm (Figure 4.2).
Colorless
Nitrite-sulfanilic
Acid
N-(1-neplxlryl
Ethylenediamin
Azoderivative (absorb
lisftt d 540nm)
Frgure 4.2: Grcisr Reaction
The advantages of the Greiss reaction are that it is simple to perfornr, cheap, precise
and accurate (Tsikas 1997). The disadvantages a"re:
F]
| *,n*,
I Reductase
I 
Nitrite I _
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l. hrterference: since it is conducted in m acidic reactioq this can lead to
interfenence by reduced thiols such as cysteine, N-acetylcysteine and
gluanhione, which then reduce the absorption to 540 nm Reduced proteins in
the acidic media may also reduce absorption
2. Nitite and nitrAe cannot be measurd directly in the plasma br1 the
reaction has to be poformed in ttre ultafiltraes (Tsikas l9y7).
3. Nifite cannot be measurd, fimtly because reduced thiols (cysteine, N-
acetylqateine and glutathione) interf€re with nitite determinatio4 4d
secondly becarse nitite may ract with sulfirydryl groups md other plasma
proteins and plasma constituems (Tsikas t997)'
4. Recovenabiltiy of nitrate after reduction to nitrite is unlnown and it is
difficult to stardardise (Tsikas lgyl).
5. During the conduction of the Greiss reaction to measure urinary nitate, the
urinary sunple is uually dilated (in ogr study it was in the order of 1:400)' As
a result this may dilate fte nitrte md give inaccurde resul$ (Tsikas 1997)'
Other Mefrods Usod to Measurc NO
NO can be measured using a ngmben of other tec'hniqus, including
immurochemical (Albrectrt 2s0),-oscillopolarography (Lu 199), fluoromerEic assay
(Tsikas 2M6),high perforrnmce liquid chnomalography Clsikas 20C6, Tsikas 2005),
nqr-infrred speclroscopy (Ohdar 195), and gas chromdogaphy-mass
spectrometry (Tsikas 1997, Tsikas 1998).
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Fluoromertric assay (Tsikas 2006) is one of the most common assays used' It is a
derivatiztion reaction, and ftene are a nunrben of modifications that can be made to
the test itself to improve sped and sensitivity. It can measure NO metabolic product
in serunu plasma and urine. It is 50-1@ tims more se,nsitive than the Greiss reaction
It can also be usd to monitor the kinetics of nifiite production from cells teated witlt
LPS or endotoxins. However, fluorometric assay is too sensitive for routine
mesurement because of i6limited linear rmge'
High perfonnance liquid cbromdog4hy (IIPLC) is mother test used for NO
measuremmt It is easy to apply and cm measgre NO in wat€r, urine and serunl
HPLC can detect both nitite md nifate simultaneously. The test is very semsitive,
rapid md accumt€ but it is timeconsuming and neds a large and expensive setup'
HPLC is not practical for routine use (Tsikas 2m6,Tsikas 2005).
Near-infrard spectoscopy is r4id, sirnple anrd less invasive' The results are not
affwted by the kidney functions (Ohdm 1D5). Gas Chromdography-Mass
Specfiomertry is also precise and accurate, and is free of interfenence. This is because
nitite can be moasured in the plasma wittrow interference from thiol groups,
sulftrydryl goups, plasma proteins (S-nitroso compounds) or plasma constituents
(fre amino acids such as tyrosine and tryptophm); there is thenefore a good r@ov€ry
of nitite and nitrae. In this method a stable isotope-labeled malogue of nitrite md
nitrate can be used as areliable int€rnal standud clsikas 1997, Tsikas 198).
Most methods discussed" and others not mentiond cm be suitable for detwting
the products of NO with a similar degree of amuracy, but each assay has its ovm
limitations.
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Other NO-related lVlarkers used as Diasnosed Tests
Besides NO, other subsfances have been used as markers to diagnose acute
rejection. These include iNOS (Albrecht 2002, Joles 2002, Albrecht 2m0) and cGIVIP
(Smith 2q4l1, Castillo 1996). Measurement of iNOS is a complor procdure; it cm be
mesured in cells or biopsie. Other substances sudt as cGMP, citulline and NO by-
products have been found to be affected by otho factors and re less reliable than NO.
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Chapter 5
Ponulation
Ethical committee approval was obtained. venbal anrd written consenrt was also
obtained from all pdients on admission All pdients recoiving their first renal
fimsplatr were includd in our study. The only qrclusion criterion was the presenc€
of aprevious renal tmsplant. Recruitned started onthe ld July 20fi2 alrd concludd
in July 2003 inthe Unive,rsity Hospital of Wales whene we recruited 50 renal allogpft
recipients (mean rye 46 * 1.93 yeaf,s, 35 males ard 15 females)' Twelve recipie'ds
Q ,A wene Live-related Allograft Donors (LAD) md 38 recipients (76V) were
cadaveric Allograft Donors (cAD). Trarsplant nephrectomy was performd in 3
recipients; 2 recipients had renal vein thrombosis and 1 recipient had life threatening
intra-opoative bleding from the renat allograft. These were excluded from further
follow-up. Out of the 47 recipietrs, 3 recipierns had previous faild renal tmplaffs,
of wtrich 2 recipients (6.4y") were receiving their second tansplalrts and 1 rwipienrt
QJV/A was receiving a third transplafr. we continud to collect blood and urine
8l
sanrples and followed theur up for 3 months. The remaining 44 recipieffi (915yo)
were primary renal tmsplant patients.
Recipients were on different tlpes of Renat Replacerrenrt Thoapy (RRT) in the
prefansplaff perio4 as shown in Table 5'l'
Table 5.1: The tlpe of renal rroplacement therapy the reclplents recelved prlor to renal allograft
transplantation
F'ollow-up Poliw
Recipiemts were followed up for 3 months. During follow-up, we collected the
following data:
l. Renal function test
2. Urine culture and sensitivity
3. Tacrolimus or cyclosporin tougfu levels
4. Odrer corrylicdions (PD poitonitis, UTI infection)
Type;mffi Reetac€med ThoaPY (RRT) Numberof
Recipe'nts
Pencat
Ilaerrodialysis
Peritoneal Dialysis
Pre'dialysis
tlaemodialysis md Peritonal Dialysis
Total
20
14
10
3
47
42.6
29.8
2L.3
6.4
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During this l2-week perio4 the following post-r€nal trmsplam complications were
observed:
1. Acute rejection proved by renat biopsy confirming acute rejection according
to 8grff97 classification
2. Unnary tact infection defined as positive urinary culture or colonies count
>100,000 PeTHPF or WCC cormt >100'
3. Tacrolimus and cyclosporin toxicity. Tacrolimus toxicity ddned as senrm
tacrolimus > lsmg/dl and cyclosporin toxicity defined as senrm cyclosporine
>250 mg/dl.
4. Increased senum credinine >!0o/o ddned as incrqse of serum crdinine
>l}o/ocompared to previous lwels of serum credinine'
5. peritoneal dialysis cattreter peritonitis diagnosed from the presence of two
of three criteria: signs and symptoms of poitonitis, positive peritoneal culture
or microscopy showing wcc >100 cells or >50% neufiophils.
Recinient Demoeranhv and Database
We developed two syst€lns for data collection: tre first system was to collect the
dernographic inforrnation of the recipie,lrts and the donors and the second systern was
devisd to collect tho labordory clinical, sample md biodremistry dAa"
Fimt Svstem
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We collected data on all recipients and donors (Table 5.2 nd Table 5'3), wtrich
included the following information:
1. StudYnumber
2. AgeofreciPient
3. Genrder of reciPient
4. Cause of ESRF
5. Type of dialysis: Haennodialysis or CAPD
6. Ihnation of dialYsis
7. Previousfrmsplants
8. Total urine outpts before trmsplatt
9. Date of tmsPlatt
10. Tlpe of trarsplaut: five or cadaveric
ll. Ageofdonor
12. Genderofdonor
13. Tissue bping
14. Causeof ddt of donor
15. Recipieirt tiszue typing cross match
16. Kidney side reciPient
17. CMV status; donor CIVIV stdus
18. Cold ischemia time (hours:mins)
19. Pre-trmsPlant medicdion
Scond Svstem
A database was created to collect all the labordory clinical, sarnple and
biochemical data Laboratory dda included number of blood md trine samples md
site of storage. Clinical data includod number of acute rejections, dde of rqiections,
histology of biopsies, fieafinent administered for acute rejections, number of episods
and dates of urinary tract infections and rsuls of culture md sositivity md
microscopy. Bioctremical data included serum credinine and tacrolimus md CsA
fough level
Data enterd on SPSS spread sheth as shown in Appendix I and2
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Causes of ESRF in ReciPients No.
7
5
5
5
4
2
2
1
1
1
I
I
I
I
I
I
1
7
APKD
Unknown
Hyperrtemsion
IgANepbropadtY
Diabetic NephroPdhY
FSGS
Hypoplastic KidneYs
Glomertrlonephritis
Nephrotic syndrome
Acute nephritis
Reflu UropafhY
Renal Calculi
HSP
Congenital
Rhabdomyolysis
Goodpasture Slndrome
Fitchne,r s SPdrome
Missing
Demography of Recipients and llonors No.
47Number of patients
Age
Sex
Mals:Femals
Transplant
Primary
Secondary
Tertiary
cAIl
I,AI)
Ischaemic Time
CAD
LAD
DonorAge
I)onor Sex
Males:Females
Causes of Donor Ir€ath
SAH
ICH
Head injurY
Others
46r14
34:L3
44
2
1
35
L2
19 + 1.1 hrs
5+lbrs
44+t4
27:2O
l6
10
3
6
Tabte 5.2: Causes of ESRF ln redpients. APKD: Adult Potycysdc Kidney lllsease; FSGS: Focal
Segmental Glomerulonephritls; ESP: Eenoch $chonleln Purpura
Table 5.3: Demography of reciplentr. cAD: Cadaveric Nlograft Donor; LAI): Ltve Allograft
Donor; SAE: Suiaraclnold Eaemorrhage; ICH: Intracerebral Haonorrhage.
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Immunosunnression
Triple ther4y (tacrolimus, azathioprine and prednisolone) was reeived W 34
recipierts: 3 recipients receivd low dose tacrolimus, sirolimus ad prednioslone; 7
recipients wer€ recruited in the ELiTe Symphony Trial (gp-A 2 received
cyclosporine, MMF alrd prednisolone, gp-B: I received zeryalx (5 dosc over 8
weeks) low dose tacrolimrs, MMF, prdnisolone, W'C 2 received zenapax (5 dosc
over 8 weelss) low dose sirotnus, MMF, prednisolong gp-D: 2 receivd zenapar (5
doses over 8 weeks) low dose cyclopsorirg MMF, prednisolone)'
The 3 recipienb with prwious failed remal allograft tansplants wene given
tacrolimus, MMF md prednisolone.
Manasement of Acute Reiection
Biopsy-prov€n acute rejection was teded with three doses of methyl prdnisolone.
persiste,nt acute rejwtion proven by repeat biopsy and failure to respond to steroid
therapy was trded with OKT3. orrt of the 19 recipients with biopsy-prove'n acute
rejection, 3 recipielrts had persistent acute rejwtion and required OKfil therapy.
Blood Samnle Collection
A total of 1178 blood samples were collected over the peniod of 12 weeks. Blood
samnles werrc collected in the momine boforc the rccioients brcke their fast
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btood samole was obtalned.
On admission, l0 mls of bloodwere collectd from the palienr8 (pre-tansplant/day
0).
Blood md urine samples wene also collected on the ftst day post reral transplmt.
Thoeafter, sanrpls were collected on alternate days. Once dischargp4 the recipients
were followed up and blod ard urine were collected at eve,ry outpaiient visit. Any
associatd complications were notd. ffthe recipier$ was admittd then samples were
collected on altemate days.
Blood sanrplc were collectd in blood botttq thd contained lithium-heparin as an
arti-coagulant (Sarst€dt Monovett@) md uine samplc were collectd in sterile
empty gniversal containers. Blood md urine samples were placed immediaiely on ice
md trmsported to the laboratory and processed within two-four hours following
collection
Blood samples were centrifuged d 800 G for 20 minutes and the senrm collected
md then stored d -80oC to be analysed ar a later dde.
rine sample was seff to be tested for crrlture 6d 5ensitivif, which is an in-house
policy for all recipien8. During the first weeb urine was collected from the catheter
(urinary catheter are takem out 7 days post renal trmsplantation) and subsequeftly
MSU whenever possible. Another sample of uine (5 mls) was sent to be mqsured for
urinary creatinine.
Btood Samole Collections fmm llealthv Vohmteers
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We recruited 10 healthy vohmteers: 4 doctots, 2 labordory technicians and 4 staff
ngrse6. The group included 5 males and 5 female with a mean age of 45 years' Wo
collected btood samples wittrout any dietary resfiictions. T?re blood saryles were
processed as mentioned above.
RenalBionsies
ultrasound-guided core renral biopsies were carried outby transplam registrars. The
biopsies were conducted in the presence of a histopAtrology tohnician. The biopsy
specimen was fixd in formali4 ernbddd in bufrer paraffin and microwave( md
stained witr traenratoxylin and eosin, periodic acid-schifr and aldehyde firstrsin stain
The specimens were reviewd and classifid withthe use of Banff97 classificationby
a single p&ologist (DG) who did not know the rsult of our No aralysis.
In our study, 30 recipients (mean + sD Ee 45 t. 2.07, 24 mq md 6 womenr)
underwent a core needle biopsy, yielding 58 biopsic of which 4l showed acute
rejection in 19 recipiem (meam We 42 L 1.72,15 male and 3 female) and 27 showed
no rejection in 13 recipients (mean age 4?*2.68,9 male ard 3 fe'male).
The 4l acute rejection-proven-biopsic were classified using Banff97 as follows:
l. Borderline rejection
2. Tubulointerstitial with moderde tubulitis (IA)
3. Tubulointentitial with severe tubulitis (B)
4. Cellular with mild to moderde arteritis (trA)
5. Cellular wiffr sevene arteritis (trB)
6. Swere vasculan rejection (UD
t6
5
6
10
1
1
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Z. Artibody mdiatd acute rejection
Total
of the 16 biopsies which showed borderline changes for acute rejectio4 only 1l of
those were treted with metlryl prednisolone; 5 episodes were not teded'
The other 27 biopsies showed the following histolory:
l0
9
I
I
I
I
1
2
I
27
Nitric Oxide Colorimetric Assav
Instnrments
The instnrments used to prepale the reagent agld perform the test are:
l. Cenfrifuge
2
4l
1. Normal
2. Acute tubular necrosis
3. Recurrence GSGS)
4. Diffirse non-specific tubula changc
5. hrfarcted tissues
6. Non-specific focal inflammation
7. Atrophic changes
8. Recovering from acute r{ection
9. Suspicoun of acute rejwtion
Total
89
2. Micro-centrifuge
3. Pipettes
4. Tubes used to store the specimens
5. Tubes ued to dilate the specimens ard performthe test
6. Incubator:two types; small md large
7. Spectrophotomete'rY
8. Software used to read the assaY
9. Printer
10. Refrigerator used to store the specime'lrs d -80"C
Princinle of the Assnv
The assay determines NO based on the enzymatic conversion of nitrate to nitrite by
nitrate reductase. The reaction is followed by colorimetric detection of nitrite as an
azo dyeproduct of the Greiss reaction (Figure 5.1).
*+ Niffie
Assay usitg
Gries Reagent
Figure 5.1: NO end-products and Greiss rcrtion
Nitric Oxide I Nitnte Redrctase\) J"
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on the day of the analysis, the samples (both blood and urine) were thawed at room
temperature. The plasma sample was diluted two-fold and the urine diluted five-fold'
The blood sample was diluted two-fold with a reaction buffer, vofiored, and 400
pmol of the prepared mixture pippetted out into a micro-centrifuge filter' We used
ultrafre@-MC microcentrifuge filters, and NMWL 10,000 Dalton (supplied by
Sigma-Aldrich); this was to deproteinise the serum to avoid attefac|'' The sample was
centrifuged at 8000 G for 40 minutes, yielding the 100 microml of serum and 300
microml of urine that were used in nitric oxide assay. For every new assay a new
sample was thawed, diluted and filtered.
All of the No rNsays were conducted under the same ambient conditions and the
same steps and procedures were used. The results of the plasma assay were multiplied
by two and the urine assay multiplied by five to correct for the dilution factor' The
tests were carried out in duplicate; it was decided that if the results were not identical
or differed by more thanZ}o/o,the assay of that sample was repeated, however this did
not prove necessary and none of the tests were repeated. All of the samples were
repeated four times for inter-assay and intra-assay accuracy'
Reasents (R&D SYSTEM)
The nitric assay involves the following reagents:
1. Nitrate Reductase
2. Nitrate Reductase Storage Buffer
3. NADH
4. Nitrite Standard
9l
5. Nifiate Standard
6. Reastion Buffer Concelrfrate
7. Griess Regeirt I
8. Griess Reagent II
Bring all reagenn (exce,pt the Nitte Rductase) to room temperdure before use'
use deionizd or distilld water whenr reconstituting or diluting the reagents, in order
to avoid nitrit€/nitate contalnination
ReastionBuff€r
Dilute 30 mL of Reaction Bufrer concentrale (10x) into deionized or distilled
waten to prepare 300 mL of Reaction Butrer (1X)'
NADH Reagent Reconstitution and Dilution:
ReconstitutetheNADH with 1.0 mL deionized ordistilled wder. AllowtheNADH
to sit for 3 minuts with genrtle agit6ion prior to use. Kee'p ti$tly capped on ice for
the duration of the assay. Immediately before use, dilute 900 mL of NADH with l'8
rnl of deionized or distilled wder. Kry on ice forthe duration ofthe assay'
Nitrate Reductase Reconstitution md Dilution
Reconstitute the Nitrate Reductase with I rnl Nitraie Rductase storage Buffer'
Vortor vigorously and allow to sit for 15 minutes at room temperdure' Vorto( again
and allow to sit for am additional 15 minute d room terrperature vortex again Keep
on ice for the duation of the assay.
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Immedidely be,fore use, dilute the Nitrate Reductase using the below equation
Determine the number of standard md sarrple wells to be usd (do not include
btmks). All sarrplc and standards should be assaryed in dupliete. Use the following
formila to dilute the Nitrate Rductase reagent:
a. Nitrate Reductase LL) = (# wells + 2) x l0 
-L'
b. Reaction Buffer LL) = volume from step ax l'5'
c. Add volume from steps a anrd b to atube, vorte'L
d. Place on ice and use wiftin 15 minut€s of dilution
Since we used the whole kit to measure the nitrAe and ceased to measure the
nitrit€, we contacted the manufiwture and anew formulawas supplied to dilutenitde
reductase; this could them be used for both fiays supplied in the kit. The new fonnula
is as follows:
a- Nitrate Reductase LL) = (# wells + 2) x 5 L'
b. Reaction Buffer LL) = volume from step ax4'
c. Add volumes from steps a and b to atubg vortst
d. Place on ice urd use within 15 minutes of dilution'
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Prenaration of Nitrite and Nitrate Standatds
Figure 5.2:
Nirrite standard - Pipette 900 pL of Reaction Buffer {1X) into the 200 pmoliL tube' PiPette ,
sid r,f- or A"action BJfer qrg intothe_ remaining tubes. Usethe200-0pm"ii:::ag*::*
to oroduce a dilurion ."*d tui,t"*1. Mix eacfr ru6e thoroughly and ctrang pip^ette tips between
;;[fi r#;t. it JeOO rrmopt statrdard serves as the high standatd and the Fleactnn
Buffer (1X) serves as the zero standard (0 pmol"L)'
100
pmol/L
50
prrotL
2s 12.5 6.25
F nolrL pmoUL Pmol/l-
't00
pmoUL
3.12
pmolil-
Figsre 5.3:
Natratc Standard - Pipette 900 pL of Reaction Bufler (1X) into the 100 pmol'll tube'. Pipetle
500 pL of Fleaclion g.rfi"t (t X) into fre. remaining tubes. Use the 1000 pmot"L standard stock
;prfi";- i AiUrion 
""ri"d tUifo"l. 
ftfix each nr6e thoroughly and cfrange. ppette tips between
each transfer. fne iOO ftmoii-sranOarO serves as the high siandard and the Reaction
Butfer (1Xi serves as the zero stardard (0 irmol"Li'
1000
plrcUL
50
umoUL
25 12.3
pmol/L pmol/L100pmol/L
6.25 3.12
pmoUL pmoUL
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Nitrite Assav Frocedure
Bring reagents to room temperdure before uso. It is recommended that all samples
and standards be assayed in duplicate. This assay procedure measur€s the
concenfdion of endogenous nitrite preent inthe smple'
l. Prepae all regents, working standards and samples'
2. Remove o(cess microplate strips from the plate frdne, retum thom to the
storage bag.
3. Add 200 Fl of Rqction Buffer to the bla* wells'
4. Add 50 pl of Reaction Buffen to the rero stmdard wells'
5. Add 50 pl ofNitite Standard or sanrple to the rernaining wells.
6. Add 50 pl of Reaction Buffe,rto all standard snd sample wells.
7. Add 50 pl Grios Reagent I to eachwell except fte Blankwelts.
g. Add 50 Ul Giess Reagent tr to eaci well orcept the Blalrk wells. Mix well
bytryping the side of the plde gently.
9. Incubate for l0 minutes at roomteryerature'
10. Determine the optical de'nsry (OD) of each well using amiooplate reder
set at 540 nn
Nitrate Reduction Assav Procedure
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The reconstitutd NADH and Nitate Reductase should be kept on ice throughout
the durdion of the assay. Bring all other reagenrts to room teryendrre before use' It is
recommendd that all samples and stmdrds be assayd in duplicate.
This assay procedure measures total nitite by converting nitats to nitite' To
determine the nitate conceutration in the samplg the endogsnrous nitite
concenrtdion measured from the Nitite Assay Procedure must be subtacted from the
converted nitrite conceffiation measrred in this assay procdure.
1. Prepue all regs,lrr, working standards, and sarplc'
2. Remove errcess miooplate strips from the plare frame' retum them to the
storage bag
3. Add 2m d of Reaction Buffer (1X) to the bla* wells'
4. Add 50 pl of Reaction Bufrer (1x) to the z,erc standard wells.
5. Add 50 pl ofNifiate stadard or sample to the remaining wells.
6. Add 25 pl ofNADH ido all stmdard urd sample wells'
Z. Add 25 pl ofNifiate Rductase imo all standard and sample wells. Mixwell
and coven withthe adhcive strip provided.
8. Incubale for30 minute a137" C.
9. Add 50 pl of Griess Ragent I to all wells orcerpt Blank wells.
10. Add 50 pt of Griess Reagenrt II to all wells except Blmk wells. Mix well
by tryping the side of the plde gently.
11. Incubde for 10 minute at roomtemperafire'
12. Det€rmine the optical densrf (OD) of each well using a microplate rqder
set at 540 nm
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Maior Adiustuent to Our Methodolow
We have concenfiated on moasuring senrm nitafie as an end product of nitric oxide
for the following reason:
1. We found that the measuremenrt of nitite (No? in serum ard urine were
negtigible. In the first 15 recipielts whene we measured nitite in serum md
urine, the senrm nitite was <l micromole md urine nifiite <2 micromole, and
this value did not alten withthe repeatd assay. The measureme,lrt of senum md
urine nifiate (NO-3) was more significant and coneldq well with the clinical
pictures.
2. Othen rserch groups have concludd fiat within one hour of oollecting the
blood sanple 95o/o of nitrite is convented to nitrate (Moshage 1995)' This
conclusion is confirmed by our laboratory results md thus confirms point (1).
. 
3.Nitrite entering the circulating blood reacb rapidly with oxyhaemoglobin to
yield nitate. Therefore, the synthcized nitric oxide is detected in tlrc plasma
as nitrate (Tmaka 1995).
Technical Notes
The following precagtions and notes were taken imo accoud while conducting the
mesrrem€rf of nitrde and nifiite, md should be considened when conducting future
measurerngtb:
1. Do not use the kit beyond the orpirarion dde on the kit label.
2. Do not mix reagents from differenrt lots.
3. Allow regents to warm to room temperdure bdore use'
4. The recon*itutd NADH and Nifiate Reductase must be kept on ice during
the assay.
5. When mixing or reconstituting protein solutions, always avoid foaming'
6. he-rinse the pipette tips when pipetting standards'
7. To avoid cross-coiltarnfuEtioq ctrange pipette tips befwen additions of sch
stardsd level, betwesn sample additions, and between reagent additions'
Also, use separate resenvoirs for each reagPlrt'
8. Pipette standards ard sanples to the bottom of the wells.
9. Add all othen reagsnts to the side of the wells to avoid corfamination
10. If samples generate higher valuq than the highest standan4 firrther dilute
the samPles md re'Peatthe assay.
11. Any vuiation in operafior, pipetting techique, washing techniqug
incubation time or terrperature, as well as kit age, can cause variation in
optical denstf.
12. Precagtions should be takem to avoid the contamination of suples or
bufre,rs with outside sourc€s of nitrAc or nitite. Possible sources of
contamination af,e skio saliva, foo4 drinlc, and wder'
13. Deionized or distilled waten strould be tlsed to avoid the contanindion of
reageffis withnitate or nitite.
14. Cweshould be taken in the selection of gloves and disposable pipette tips
as these producls rnaybe a source of nitrite or nitate codamindion
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Statistical Analvsis
SpSS softwue (version 18) was used for the dafa analysis. Data is presenrted as a
median value * serri-irterqurtile (semi-IQ) range. A non-parametric test, the Mann-
Whinrey Gst, was used to test for difrerenrces betwem goups. A P value S 0.05 was
considered to indicate stdistical significance. An ROC curve was usd to find the
sersitivity and specificity for various levels of sernrm nitate in diagnosing acute
rejection Age was preseriled as mean value r SD.
Renat dysfirnction caused by post tusplant complicatioru (acute rejection, UTI,
raised serum creatining PD penitonitis) can occur in the sanre recipie'lrt at the sme or
different poids in time. gimilsly, post trmsplmt complications in the 44 recipierfis
could occur at the sarne or different poids in time. This can intoduce bias in otrr
statistical analysis: to avoid this, the most ppropriate mettrod to uralyse tlrc dda is to
analyse the first adverse event that occqrrd in each ofthe 44 recipients.
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Chanter 6
Serum Nitrate in llealthv Volunters
The healthy volurfeers had medim serum nitate of 47.5 + 10.88 pmolfl.
Serum Nitrate in End Stage Rcnal Failure
We measured serum nitrate in the pro-transplant blood sanrples of the 47 recipierfs
(day 0). The mediar senrm nitte was 55 + 30.5 prmol/I., which represenrted the senrm
nitrate levels in ESRF.
Serum Nitrate in Recioienh with Previous Renal Tranenlants
t00
Tlre median nitate measured in recipienrt Nora 2l (CK) was 115 + 4o.25 pmol/I,
rwipiert Nora 26 (JF) was 55 + 27.5 pmot/t md recipiert Nora 27 (AL) was L07 +
16.5 pmotlt None of these recipie,lrts had m episode of acute rejection' but they
rmderwenrt 4 biopsies, nono of which showd acute rejection' Figure 6'1,6'2 and 6'3
show thd levels of senum nitrde re,mained high despite fafling sonrm credinine'
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rigurs 6.1: Reciplents N21 had a previour falled renal tranrplant over a 3 month perio4 he had
rerun nltrate > 70 ft on O" tn" O" day, nephrortomy wsi carrlcd out for ureterlc obrtructlon
On day 9, renal blopsy @x) was carrted out, s!;whg;cute TubularNecrosb (ATN)' On the 266
d"V, tliu necipfent haduTt Refcrence llneat70 pnoUl
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fgure 6.3: Serum nttrate of Redptent N25 grer 3 months perlod ws >7O ttttpl/tlrop th3lig:t
ioinu zr day post renat }aispta"L o" the 86 dan rcnal bxy-ere carried out, both showlng ATN'
IIII was diryiorcd on the 7to doy. Reference llne at 70 pnlL
'l02
N21
Figures 6.4, 6.5 ard 6.6 strow falling senrm creatinine despite sustained raised
levels of serumnitrate.
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Figur€ 6.5: In N27, Scmn nltrrte rnd rerun creetlnlne polt rcnd tnnrplut S creetlnine
contlnuer to frll towrrdr r norud vdue whllc rerun nltrete ilayr rt high levelr. Reference linc at
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rEurc 6.6: IN N26, Serum nltrate rnd rcrun crcrtlnlne pod renel trmrplant s creatlnlnc
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Ont of the 44 rqalallograft recipien6, 17 recipients (mean W 46,8 males ad 9
females) had SGF for the perid of three monfts post renal trursplantation They had
a median senrm nitde of 42 + 14 pmol/I. The serum nitafe fell to low levels for tho
duration of fre follow-rp (3 morntrs). The graphs in Figure 6.7,6.8,6.9, 6.10 md 6'll
demonstatethis.
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rEgre 6.7: Serun nitrate ln Nora 16 durtng the 3 month perlod port renal tranrplant over 3
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B.igure 6.g: The medlan serum nitrate ln Nora 10 durtng the 3 month porlod post renal transplant
,", ae.S pmoUl Ono eplsode of UTI dld not cause a rfue in serum nltrate" Reference llne is 70
pnol/l
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figure 6.9: The medisn serum dtrate ln Nora !E durlng the 3 month p€rtd port renal tranrplant
war 30.5 ymol/l.
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FigUre 6.10: The medlan serum nitrate in Nora 19 durtng the 3 month perlod post renal
transplant war ZFnoUl .
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Figgro 6.11: The median gerum nitrate in Nora 15 during tho 3 months period post rend
transplant was 43 F^noUL
Urinary tract infection did not cause a rise in senrm nitrate in recipients vrith SGF,
as shown in Figures 6.7 alfl6.8, md Figures 6'12, 6'13, 6' 14 md 6' 15'
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Figure 6.12: In Nora 1, IITI doet not caure a rlgplffcant rlse ln serum nttrate' the medlan somm
nitrate was 54.fl1 PnoUL
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Figure 6.13: In Nora 5, UTI does not cause a rignlficant rise in serum nttrate' Ihe median serum
nitratewar 34 P'moUL
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t.igure 6.15: In Nora 12, IITI doec not caute a rignificant rlse in serum nitrate" The median
serum nltratewas 39.5 PmoUL
Serum Nitrate in Biopsv-nrovon Acute Reiection
The median senrm nitae in the recipients with biopsy-provelr actrte rejection (65.5
+ 40.75 pmofl) was significarfly higher when compard with senrm NO3- m
recipiems without acute rqiection (41.5 t 13.25 pnol/l) (Table 6.1).
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Post Tlznsplant
Conphcation - Acute
Reiection
Recipient No. Medianof
S nitate
(ltnon)
Semi-IQ
Range
Manr-
Whitney
Exact Srg. (2-
tailed)
S nitrate in reciPienrts
with AR
S ninate in reciPients
withoutAR
36
65.5
4L.5
53
23 0.001
Table 6.1: The medlon serum nltrato war rlgnificantly htgher tn recipbnts wlth biopry-proven
acute reJecdon compared to redplents wlthout acuto reJectlon
Using an ROC and setting the tbreshold d70 Fmol[ (between 68 md 80 pmol/l)
(see Table 6.2) weget a sensitivity of 50% and specificity of X)o/o.
Thaefore, using the coordinates of the curve and moving tle theshold will alten
the sensitivrty ard specificity of senum nit6e during acute rqiwtion (Table 6'2)'
Serum Niffie Sensitivity 1-Specificity
13
16.5
20
22
24
l.
o.94
0.917
0.889
0.778
110
26
2E
30
32
34
35
37
38
39
42
u
45
I
0.875
0.875
0.875
0.875
0.875
0.875
0.750
0.750
0.750
0.750
0.625
0.5
0.5
0.5
0.5
0.750
0.750
o.122
o.694
0.639
0.5t3
0.556
0.500
0.472
0.417
0.361
46
49
5l
52
57
6l
68
EO
87
92
L02
1ls
r22
0.5
0.5
05
05
o.375
0.375
0.375
0.2s
0.250
o.tzs
0.00
0.306
0.306
0.278
0.250
0.222
0.L94
0.139
0.111
0.(m
0.083
0.056
0.028
152
r80
0.028
0.00
0.00
0.00
Table 6.2: Cmrdindes of ROC.
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During acute rejectiorL s€rum nitate is orpectd to rise md &op with successfiil
treaffircilrt of acute rejection If acute rejection persisted or failed to respond to
teaffieirt we oryected the levels of sorum nitate to remain higlt
RecipierfNora23(Figrrre6.16)developedasing|gepisodeofac-uterejectionthd
was treafed zuccssfully with methyl predinsolone. Acute rejection was associded
with a rise in s€,nrm nitrafe fs 125 pmolfl and when fieded succesfully serum nitrate
fellto 17 pmol/I.
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X'lgUre 6.16: SeIum nttrat€ rlsec during acute reJecdon and falls to levelr < 70 FmoUl when
treated ruccerefullY.
l'i.2
Recipierr Nora I I had two episodc of acute rejectioq, both wene associaed with a
rise in serum nifd eto72 prnol/l and 70 tunon md following successful tednent
senrm nitate was 53 pmol[ urd 42 pmou rospectively. Ttris recipienrt also had one
negative bropsy during which senrm nifde was 19 Fmotrfl (Figure 6.17).
Ftgure 6.17: Nora 11 had two episodes of acute reJectlon n_Tt!-:pfodes it was associated with
a r{se in gerum nitrate > 70 pmoul and when treated rucceorfully thir lwel falls to < 70 pmo/l
Recipied Nora 22 had a rise in senrm nitate to 80 pmo/l with biopsy-proven acute
rejection. Following treafinent with methyl prdnisolone the level of senum nitde
was 38 pmofi. Intoostingly, senrm creatinine remaind high (250 mmol/l), $frich
lead to a second renat biopsy which showed recovering episodes of acute rejection
Serumnitrate continued to be low (30 pmol/l), md re,nal firnction normalised without
any furtlrer fieatnent (Figre 6.18).
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Figue 6.18: In Nora 22 cerum nltrate dset durlng acute rejodlon and falls once sucoessfully
treated. The recond blopoy war taldng becaure of hlgh serun creatlnlnp whlle rerum nltrate was
within nomal limlb.
Two Roipients (N9 md N3) had pe,rsisted rejection and required oKr3 thoapy'
Failure of treatm€nt with mettryl prednisolono of acut€ rejection episodes was
associated with high levels of senrm nitate. Only succssful featment of acute
rejection wittr oKT3 was associated witlt fall of senum nirane (Figuro 6.19, Figure
6.2O).
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rigure 6.19: In N9, 3 episodes of AR wlth rlse ln gerum nltrate (f8 pmou, 72 1nolfi'' 143 pmoul
ffipotpuvl which fellio levels < 70 p,moUl (45 pmol/I) onlywhen acute reJectlon was resolved by
successfd troatment wtth OKT3.
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Fi$re 6.20: In N3, serum nttratc rlss with acute reJectlon (179 pmolft 125 pmoUl' 120 pmoUl
"olpoA"a9 but 
does not fall to levels < 70 pmoUl untll tread ruccessfully wtth OKT3 to serum
nitrate 43 pnoUl.
t\bra 3
il5
One recipient (N13) (Figure 6.2L\ han pensistent rejection and did not rcpond to
methyl prednisolone therapy or to fieafinent with OKT:I; his senrmnifiate levels were
persistently high throughout The recipimt lost the kidney transplant
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Figpre 6.21: Inthis reclplent peroistent reJectlon was assoclate4 as expected, with a prristent
rlss tn serun nttrate In thtr rltuatlon the graft was lost'
Ttris would include the following complicdions:
1. Urinary tact infection
2. Tacrolimus toxicitY
3. Raisd senrm crdinine >loo/o
4. Peritoneal catheter peritonitis
n6
SerumNitrate in UTI
Thene wene 71 episodes of UTI in 37 recipietrs (aged 47,26 nnles and l1
females).
The cultgrs showed 10 different tlpes of orgarism (Table 6'3): the commonest
isoldd organisms were ent€rococcus 82.3Yo) md E.coli (l7.7yo). All episodes we're
treatd successfully with oral antibiotic according to senrsitivity, irrepective of the
number of colonis or the wtrite cell count in I{PF'
Typeof Oryanism Frequency Percentage
Ente,rococcus
E.Coli
Candida
Streptococcrrs
Coliform
Vancomycin Resiste,lrce Enterococc'us (VRE)
St4trylococcus
Proteus
Pseudomonas
V. Faecalis
E.coli & Candida
42
23
L7
t7
l5
8
4
1
I
I
l1
I
I'
32.3
tt.7
13.1
13.1
11.5
6.2
3.1
0.8
0.8
0.8
0.8
Table 6.3: Dlffercnt t5'pes of organism in recipient*
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There was no significant differ€nce bemveen the medim serum nitate duing
e,pisode of UTI (21.83pmo1/l) vihen compred with the median senrm nitrde Q2'61
pmon) during normal urinuy cultures (table 6'a)'
o* of thp 44rdpietfis,40 recipients (mear a$e46yem' 28 men 8'ld12 women),
were taking tacrolimus. Thene wene 128 episodes where tacrolimus level was >15
ng/dl. only I recipient (33 years old, male), on cyclosporine, I:rrd 7 episodc were
CsA tough levels woe >250 ngldl.
Mann-WhitneY
ExactSig. (2-
tailed)
Scmi-
interquantile
Ranges
Medianof
S nitrate
@mon)
Rcipient No.Post Tmnsplant
Complication - Acute
Reiection
S nimrs in reciPients
withUTI
S nitrace in roiPients
witlt normal urinarY
culture
Plentr with UTl and
those wlth normal ur{nary culturor.
1r8
The median serum nitrate duing tacrolimus toxicity was not significalrtly higher
when compared to median senrm nitate in recipients with normal tacrolimus frough
levels Table 6.5)
serum nltrate ln reciPlents
and reciplents wlth normal tacrollnur levelc.
Senrm Nitratewith Rise in Serum Crcatinine >l0olo
Out of the 44 roipients, 40 recipients (mean age 46 + 2.05,31 males std 9
ferrales), had at least one episode where there was arise in serum creatinine >107o In
total, there were 100 insAnces of a rise in senum seatinine >llo/o in the 40 rwipients.
Thene was a no significant difference of medim senrm nifiat€ dtring the rise in s.
creatinine >l}o/o when compared to ndim senrm nifiate during normal levels of
senrm cr@tinine (Table 6.6).
Post TransPlant
Complication - IT
RecipientNo. Median of
S nitrate
0moUI)
$mi-
interquantile
Range
Mann-TYhitcnY
ExactSig. (2-
taited)
S nitrate in reciPients
wittr TT
S nitate in reciPients
with normal tacrolimus
troug[t levels
22
22
35.5
45
14.88
L5.12 0.205
wlth Tacrollmur odctty GT)
ll9
Post Transplant
Complication- Risein
S Crcatinine>l0o/o
RecipientNo. Median of
S nitnate
GmoUI)
Ssmi-
intequantile
Ranges
Mann-WhitneY
Exact Sig. (2-
tailed)
S nitrde- in rwipierfis
with rise in s.creatinine
>LOo/o
S nitrat€ in reciPieG
with normal senrm
cr@tinine
13
3l
4
40
10.5
17.5 0.554
ln rerum in wlth a rire in Jerum
and those wlth normal rerum creatlnins
Table 6.6: No rlgniffcant
Serum Nitrate in Perltoneal Diatvsis Peritonitis
Five recipien6 (mem age36+ 3.98, 3 males and 2 femals) out of the 4 rwipienrts
had PD peritonitis confirmed by culture ard sensitivity and rquiring surgical removal
of the pD cdheter. There are no significmt differenrces in the median serum nitate
betwe€n recipients with or without PD peritonitis (Table 6'7)'
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ManrWhituey
Exact Sig. (2-
tailed)
$emi-
interquantile
Ranges
Median of
S nifiatc
funoUt)
RecipientNo.Post Tmnsplant
CompHcation-PD
Peritonitis
S nifate in reciPieffi
with PDP
S nifate in recipients
withno PDP
ients with or without PIIP'
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Chanter 7
Discussion and Conclusiou
Finding an altemative test to diagnose acute rejection has always been an dtractive
prospect to rserchers. NO is a molecule which plays a role in acute rejection It
contribrfes to orgam firnction during phpiological states and pathological conditions
depending on the type of NOS activated @avies 1995). Unde'r ptrysiological states, it
is the cNOS which is up-regulate{ genrerating small amou$ of NO which is
cytoptrotective md facilitats physiological fimctions @adomski 1990). Up-
regulation of iNOS genends large amouffi ofNO. This occurs during acute rqiection
and inflanrnatory conditions. The small amormt of NO produced by cNOS forms
nitrite and is difficult to mesure, while NOS-generdd NO is produced in large
quantities, forms nitrate ad is detectable in the blood (Monis 199f, Weigh 1998,
Jefayri 2@0, Goligonky 2W2). The production of NO in large arnounts dwing acute
rejection and the possibility of measuring it inthe poipheral blood samples makeNO
measurem€Nrt an dfractive twt.
r22
ESPJ md renal tansplarrtation cTeate a pool of complor and infiguing
enrvironments for NO. NO production in ESRF is afrected by the patlrology md by
re,nal replacement therapy (HD or CAPD). On the other harrd' NO in renral tansplant
recipients is influenrcd by the process of transplanatioq organ refiieval, surgery'
immunosuppresion and post tmsplant complications, whiclt include acute rqiection
and oppornrnistic infections.
ESRF patisrts have a high median senrm nitrde level (55pmoVl) irrespective of the
type of renal replacenrern ther4y they were receiving. Ttris could be dtributed to the
cause of ESRF and the role of NO. Once the pdient undergos a succssfrtl renal
transpla4 the serum nitate drops to values comparable to those in healthy
volunters. This is because the tansplanted kidney restores the normal NO
production/socretion mectwrism in addition to st(cretion of endogOnous NOS
inhibitors.
The vascularity and size of the transplantd organ" as well as the numben of
previously fansplanted orgaut, may increase the total body NO production Langrehr
et al were the first to conclude that thene is an increase in the total body No
production dwing the rejection of a vascularized organ (Langrehr 1992'). Pdierfs wittt
previous multiple trursplants may have high serum nitde levelso which could be
cagsed by the vascrrlariry of the newly-transpldted hdney and the presence of
prwiousty tansplanted orga6 which may not fipction, but may contribtrte to the
toal body NO production and haemodynamically active/renal NO production Our
rgsul6 reflect the fact that althoWh these recipients have a normally-firnctioning renal
allograft trursplant they continue to have high senum nitrAe levels which behave
differently to the primary renal tamplurt recipients. This could be due to two
possible reasons:
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l. fui increased total bodyNO production and haemodlmamically activdrenal
NO production 
- 
more than cm be handled by the tansplanted hdney and/or
2.T\efaild or failing previous renal transplmt which continues to corfribute
toNO Production
Despite the high senrm nitate levels in these recipients, serum creatinine falls to
normal valus. We havs been the first to observe high levels of senrm nifiato in multi-
trmsplafr recipien$; as far as we know there re no previous studies reporting any
such associdion Howevoo tltis study includes a small number of patierfs wittt
previous faited transplants and may ned furttrer researcb- The possibility thd this is
only a rardom observation cmnot be nrled out
In the study g1oup, there were 17 recipienf with stable gfaft fimction Their senrm
creatinine and senm nitat€ dropped down to normal levels following fimsplmtation"
None of the recipients were subjected to dietary restriction orcept erly moming
fasting until the blood sanple was collected. Tlre medim senrm nitate in SGF was
42 + 14 tmoll (with a range of 15-60 pmol/t) depite their vdiable dierb. The fall in
senrm nitrare levels towards normal in recipients with stable gpft functions shows
thd the transplanted hdney achieves normal No metabolism and shows the role of
tlre renat system in clering NO, as welt as confirming the normal or orpected rmge
ofNO emd-products (serum nitrate) in humms.
Recipients with acute rejection show a significant rise in senrm nitrate when
compared to recipients with SGF and those with negative renal biopsies. Our rsults
confirm the results of similar prwious work Lmgfehr, using a sponge mtrill
showd a rise in nitritc and nitrate in the sponge fluids and a rise in senun nitrite
and nltrate dgring acrrte rejection in solid orgdr fansplantation in rats (Langrelr
lgg2).There was a rise in the level of serum nitntc duing acute rejwtion in rat renal
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fimsptatrs (Suzuki 2004,Ln1999), rd pancreatic transplants Clanaka 1995), rat livs
fiansplants (Ohidar 1995) ard rat lung transplants (Shirashi 1995)' Most humm
studis involving renal tansplantdion have shown an increase in the levels of serum
nitate dgring acute rejwtion (Smith 1996, Takatrashi 1998, Koyma 20W, Albrech
2000). However, we measured only senrm nitrate, recruited a largen numben of
recipienrts, followed-up for a longer period and imposed no dietary restriction except
for fasting prior to harvesting of the blood sample. We found senrm nitrate levels to
be significmtly higher in acute rejectioq while serum nitite level was low (< I
micromol/l) at all times. This is supportd by the published reserch tlnt nitrate is the
predominmt blood oxidising product of NO ard the indirect marker of the level of
NO production Howeven, senrm nitritg in addition to serum nitrate, was usd in
diagsosing acute rejection (Ricart'Jand 2001, Viinilka 1996, Hibbs lW\ Moshage
1995, Wennmalm 1993, Lmgrehr 1991, Langrehr 19v2, Lngrebr 1993, shiraishi
1995, Ohdan 1995, Ddoglu 1996, Atbroht 2000, Tmaka 1995, Takahashi 1998, Lu
1999, Castillo 1996). This is becarse the methods make it possible to det6t nitde
alone, nifite alone or both However, the recove,ry of nitrite from whole blood
samplc kept on ice or d room tsmperdure for two-five hours was 0-?% while the
recovery of nitate wu 9l-95o/o. This is because of the red cells in the uihole blood
samplg which oxidise nitrite to nitr*e (Mostrage 1995, \Yormralm 2W7}
Furthermore, the normal nfuae level in humm serum is 30-60 pmol/I, whe'reas the
normal nitite levels are 0.5-3 Fmoyl; therefore the reported senrm levels of the sum
nifiite and nitate in the serum repreerrt tlre nifae concerrtrrdion In addition'
anticoagulants in blood sample bottles may interfere with the quatification of nitrite
(Tsikas 2W6). Thenefore nitrate is the final end-product ofNO'
12s
We have showr a significant association between NO production and acute
rejection Howeverr, to make this tct clinically applicable we need to ideffi8'a level
at which acgte rejwtion is diagnosd. There were 19 recipients who had a biopsy-
proven acute rejection with a median senrm nirarc of 66 +' 53 pmol/I, which was
significantly highen than the medim serum nitrate in the 13 recipients with negative
biopsic (42 * 6 pmolt) and the rwipients with sGF (42 + 14 pmon). Furtlrermore,
during acute rejectioq serum nitrde rises to levels > 70 pmol/l and falls to 'normal'
valuq (<66 micromovl) with successful tannem - as diagrurmdically displayed in
Figurc 6.16, 6.!7,6.18, 6.19 and 6.20. SimilarlS recipients with penistent acute
rejection had serum nfuafe levels > 70 pmolfi br$ th65e fell to levels of < 70 pmoUl
only whe,n acute rqiection was successfully tr@ted with OKfil' On the othe'r har{ the
reported normal levels of senum nitate in humars is 3060 micromol/l' In the
voluffeer gfoup, the mdian senrm nitr$e level was 47.5 * 10'88 pmol/l' while
recipierfs with stable gfaft finction had a mdian senrm nitate of 42 + 14 pmolA'
Both groups fell within the reported range. Therefore, in acute rejection" serum nifrde
rises to levels > 70 pmolfi wtrile in tlre absence of innnune response md in
ptrysiological states, the serum nitrate falls to values < 70 pmol/l' Thus, senrm nitate
at ?0 micromoul has a low senrsitivity (50olo) but high specificity (90y"). However, as
we showed using the ROC coordinate, the value of serum nitrAe chosen can change
and, accordingly, the sensitivity and spwificity can change too. Choosing a lower
serutn nitrat€ level, therefore, will improve the sensitivity of the test'
The,re was a significmt rise in the medim serumnitrae level dwing acrrte rejotion
compared to the othen post tmsplant complicdions. This fi5ther supports the
association betwm senrm NO production and acute rejoction, md the usefirlness of
measuring senrm nitrae as a diagnostic test.
'126
UTI is m infectious process and the second-most 6ommon corrylication in renal
fimsplaff recipieds, md studies have shown an associated rise in NO production
(Kang 2004, Poljakovie 2003, Wheele,r lggT).It causes renal impairmenq manifesting
as a rise in serum creatinine; it is also r€port€d that serum NO risgs during acute UTI"
particularly senrm nitite. Howeven, in our goup of recipients, episodes of actlte UTI
were not associdd with a rise in senrm nifrate'
A second condition is poitoneal dialysis peritonitis, an inflamm6ory proc€ss
which could be associatd with up-rquldion of iNos and incrased production of
NO. However, there was no significant rise in serum nifiate in this condition either'
A rise in serum creatinine >L00/o was not associated with a rise in serum nitrde'
Rise in serum creainine >l}o/o indicate renal dysfunction and the recipio$ may
require a renal biopsy to rule out acgte rejection Thus, low levels of serum nitate
may avoid ftis invasive procedtrre.
Most of the immunosuppresive drugB used to control acute rejection' such as
tacrolimus or cyclosporine (Wdarai 2Cf,4, Stwdkovfl 2001) md corticosteroids
(Radomski 1990), $e known to inhibit Nos and No productiorx In
immunosgprqsive toxicity there is renal dysfirnction Although high levels of
tacrolimus >15 ngldl or cyclosporine >250 ng/dl may clench the diagnosis,
occasionally it is difficult to differentiate drug toxicity from acute rejection However,
serum nitrAe dose not rise during immunosupprcsive toxicity' Thereforg low serum
nitrate levels and high drug trough levels will support toxicity ralher than acute
rejection
Dietary restiction during nitrate analysis is controversial. In our study we did not
impose dietary restiction with the exception of fasting before blood sample
collection In healthy voluntee,rs the median senrm nit$e was 47.5 + 10'88 Fmol[
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(range 24 - 77 tmol,/l) without dietary retriction. This was comparable to reported
values by other studies (30-60 pmolfl) without ary dietry rstriction and using
different methods (Tsikas 2W6, Green 1982, Suthanthiran, Blum 1998, Sclmidt
1999, Viinikka 1996). Not all investigaton imposed dietary restictions on their study
goup (ufrettrcr animal or humm) (Langretg 1992, Shiraishi 1995, Tanaka 1995,
Dedogfu 1996, Pail 1996, Takahashi 1998, Lu 1999, Smith 1996, Koyama 2000,
Wennmalm lgg3'),howeven, md continued to us€ s€Ium nitrate or NOx as a test to
diagnose acgte rejection in various orgm fiansplaffi; they derronstrated a significarf
rise in senrm nitrde or NOxduring acute rejwtion we do not believe that the absence
of dietary restriction in our recipients (although otg blood sampling was done while
the patient was on an ovo-night fasting regime) atrect€d the results, for the following
reasons:
1. During an episode of acute rejectioq there is upregulation of iNOS leading
to the production of No in such large qumtities thd the serum nifate would
not be affected by the diet of the recipient or any other source.
2. O11lerrgsqrch groups have demonstrded the usefirlness of senrm nitate in
acute rejection without dietary reshiction
3. All rwipients with stable gfaft function had s€rum nitrde comparable to
thd of healthy volunteen despite not being zubject to dietary restrictioa
Wennnala et al conductd a study in healthy volunteers and in patiurts with
congestive cardiac failure awaiting a heart transplant. The pupose of the study was to
orplore rhe NO metabolism and orcretion in humars. No dietary resfriction was
imposed. NO was administened by inhalation in inoeasing doses to both groups. They
reported a dose-relded increase in serum nifde, but senum nitrit€ did not change
significatrty (Wennmalm 1993). In fact, they dernonstated ft* nitrite is degpaded to
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nitate whe,lr the whole blood sample is incubad in vitro for ove,r two minutes. This
clearly demonsfdes thd dgring conditions of increased NO productiorU prticularly
during pathological conditions whene there was up-regulation of tr'{OS and production
of large quantities of NO, there was an associded rise in serum nitrate to m e'(e|ff
ttrat it is not affested by the dietary intake of nitr6e (Wennmatm 1993, Wenrrmalm
r99z).
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Conclusion
Nitic oxide is a complex, unique molecule. Althougfr we have a clear
undensgnding of its formdion, meclranism of action md degfaddion in vivo, its
exte,lrsive role in pathophysiological conditions adds to its complex ctraacte'ristics
rather tfran shedding more light. Evidoce supports NO's role in acute rejectiotU
irrespective of its precise role, NO has been exploited as a marker or test to diagnose
acute rejectio4 th€reby avoiding renal biopsy.
lVe conclude from our study and resulf that senum nitate is the final end-product
of NO md that it is this molecule which should be measured in serunL ud not nifrite.
Our results slrow that thene is a significant rise of senrm NOr- in acute rejectioq
therefore senrm NO3- levels >70 pmol/l indicafe hig! possibil$ of acute rejection
on the other han4 in the presence of other post r@al nmsplant complicarions (uTI,
drug toxicity, DGF, raised senrm oeatinine >107o) with low serum NOI- (<66
micromoydl), the possibility of aorte r{ection is low and thenefore we can avoid renal
bropsy.
Clinically, post tmsplmt complications may ocaur simultaneously it becomes a
clinical challenge to orclude or pfove acute rejection and reiral biopsy may be needed
just to rule ogt acute rejection Howeve,r, our resulb demonstrde that serum nitrate
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rises only with acute rqiection Thenefore, where the cause of renal dysfirnction is
difficult to stablish, measurom€lrt of senum nifiafe becomes helpful' High levels of
senrm nifats may indic$e acute rejection and er(clude othe'r post tmsplaff
complications, utd thus renal biopsy becomes justified. Howwer, low levels.of sonrm
nitrate do not rule out the possibility of acute rejection, and in the presence of othen
possible post trarsplad complications such as UTI or tarrolimus toxicity, or a rise in
senrm cratinine, may avoid the roal btopsy'
l3l
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